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RESUMEN 
 
Introducción 
 
El endometrio es la capa de mucosa que recubre el interior del útero y consiste en 
un epitelio simple cilíndrico con o sin cilios, glándulas y un estroma rico en tejido 
conjuntivo y altamente vascularizado. Durante cada ciclo menstrual, el endometrio 
sufre una serie de cambios en respuesta a fluctuaciones en los niveles de las 
hormonas esteroideas procedentes del ovario. El endometrio se divide 
histológicamente en dos capas, la capa basal, la cual ni responde a las hormonas 
esteroideas ni sufre descamación, pudiendo regenerar una nueva capa funcional en 
el siguiente ciclo menstrual. Mientras que la capa funcional si responde tanto a la 
progesterona como el estradiol, descamándose durante la menstruación.  
La capacidad excepcional de renovación y regeneración del endometrio de manera 
periódica y que además puede hacerlo durante toda la vida de la mujer con un 
apropiado tratamiento hormonal (se considera que esto ocurre aproximadamente 
400 veces durante la vida reproductiva de la mujer), lo hace un tejido candidato 
para la existencia de una población de células madre somáticas (CMS) que sean las 
responsables de esta actividad.  
Las CMS, son definidas generalmente como células indiferenciadas pero que se 
encuentran entre las células diferenciadas de un tejido u órgano, y que pueden 
renovarse tanto a sí mismas como diferenciarse, dando lugar a los diferentes tipos 
celulares especializados que forman los tejidos. Así pues la función de éstas 
permite la adecuada homeostasis con el fin de mantener y reparar el tejido en el 
que se encuentran.  
En el caso del endometrio, dada su excepcional fisiología se hipotetiza sobre que 
estas células madre somáticas sean las responsables de esta actividad cíclica de 
renovación y en determinados casos sean también las responsables de 
determinadas patologías endometriales como endometriosis y cáncer endometrial. 
En los últimos años, diferentes estudios apoyan esta hipótesis, donde se postula 
que las CMS endometriales pudieran estar localizadas próximas a los vasos 
sanguíneos en la capa basal.  
  
 
Debido a la ausencia de marcadores específicos de CMS endometriales, el fenotipo 
Side Population (SP) se ha establecido como la técnica más usada para aislar CMS 
en los diferentes tejidos. La SP se basa en la capacidad de las células para excluir el 
colorante vital Hoechst 33342 a través de los transportadores de membrana ATP, y 
fue originalmente descrita como marcador de las CMS de la médula ósea. En el 
endometrio humano, varios grupos han demostrado la existencia de células SP con 
características de CMS, donde entre otros aspectos, se ha descrito su papel clave 
en la regeneración del endometrio in vivo. 
Posible aporte exógeno de CMS 
Por otro lado, las células madre de la médula ósea (MO) tienen la habilidad de 
diferenciarse en múltiples células no hematopoyéticas. Diferentes estudios 
describen que en pacientes que recibieron un trasplante de médula ósea, las 
células derivadas del donante fueron capaces de diferenciarse a hepatocitos, 
células de músculo esquelético, neuronas o piel, dependiendo del ensayo clínico 
realizado. 
Además en estudios donde mujeres eran trasplantadas por médula ósea de varón, 
las células provenientes del donante eran capaces de diferenciarse a células 
epiteliales y estromales en el endometrio de las receptoras. Ello sugiere una posible 
fuente exógena para la regeneración del endometrio que se puede producir 
después de la movilización de células de la médula ósea, ya sea como un proceso 
fisiológico normal o en condiciones patológicas como la quimioterapia previa al 
trasplante. 
Parte de nuestro estudio pretende abordar la cuestión de si las células de la MO 
derivadas del donante contribuyen a la población endógena de CMS representada 
por la SP endometrial y por lo tanto conocer el posible origen de esta población 
celular, o saber si únicamente actúa como aporte exógeno de CMS.  
Búsqueda de marcadores específicos de CMS 
Uno de los retos de la biología celular y la biomedicina es la búsqueda de 
marcadores específicos de CMS. Dado que ello beneficiaría el aislamiento de estas 
células y su potencial uso terapéutico en medicina regenerativa. En los últimos 
  
 
años, se han descrito multitud de marcadores atribuidos a caracterizar las CMS en 
endometrio, pero ninguno hasta la fecha relevante.  
Recientemente, Clevers y colaboradores, han conseguido identificar CMS en el 
intestino delgado de ratón a través del marcador Lgr5. Muy brevemente, Lgr5 es un 
miembro de la familia de receptores acoplados a proteínas G, que contiene 
dominios ricos en Leucinas, y que se encuentra implicado en la ruta se señalización 
Wnt (ampliamente descrita en la biología de las células madre). La expresión de 
Lgr5 es específica de las células epiteliales columnares que forman la cripta 
intestinal; además se ha visto que estas células Lgr5 positivas son capaces de dar 
lugar a las distintas células que forman la cripta intestinal, mostrando 
multipotencialidad, característica propia de CMS. 
La expresión específica de este marcador Lgr5 propio de células madre intestinales 
(tejido derivado de endodermo) también ha sido descrita en tejidos como el 
folículo piloso (tejido derivado de ectodermo) o recientemente en riñón (tejido 
derivado de mesodermo), lo cual hace pensar que podría representar un marcador 
universal de CMS.  
Objetivos  
Los objetivos principales que se han establecido en la presente tesis son: 
1. Demostrar la contribución de la médula ósea como una fuente exógena de 
Células Madre Somáticas para el nicho endometrial.   
2. Investigar la expresión del marcador Lgr5 para identificar el nicho de Células 
Madre Somáticas endometriales.  
Los objetivos secundarios que se derivan son: 
1.1 Identificar las células portadoras del cromosoma Y en el endometrio de las 
receptoras trasplantadas de médula ósea y caracterizarlas mediante 
inmunohistoquímica. 
1.2 Analizar la longitud telomérica en los endometrios de las receptoras 
trasplantadas de médula ósea. 
  
 
1.3 Investigar la contribución de la médula ósea a la población Side Population en el 
endometrio de las receptoras trasplantadas de médula ósea. 
2.1 Investigar la presencia del marcador Lgr5 en el endometrio humano a lo largo 
de ciclo menstrual.  
2.2 Correlacionar las células Lgr5 positivas a nivel de ARN mensajero con su 
longitud telomérica como posible característica de célula madre.  
2.3 Aislar las células Lgr5 positivas e inyectarlas en la cápsula renal de un ratón 
NOD-SCID para evaluar la formación de tejido endometrial humano. 
Metodología 
Para ello, se ha establecido el siguiente diseño experimental:  
1) En relación a la contribución exógena de Células Madre Somáticas 
endometriales:   
Para el análisis de la contribución de la médula ósea a la regeneración endometrial, 
se ha creado un modelo de trasplante de médula ósea entre donante y receptor de 
distinto sexo, siendo posible distinguir la contribución de la médula ósea por la 
presencia de células portadoras del cromosoma Y (donante)  en el endometrio de la 
receptora a través de hibridación in situ fluorescente (FISH). El análisis fenotípico 
de estas células se realizará con marcadores específicos como son CD45 (origen 
hematopoyético), CD9 (epitelio) y Vimentina (Vm, estroma).  
El análisis de longitud telomérica se llevara a cabo con la técnica del telomapping, y 
la evaluación de células Side Population por citometría de flujo como la población 
de CMS endógenas en el endometrio de la receptora nos permitirá determinar la 
contribución de la médula ósea así como la posible correlación de las diferentes 
fuentes de células madre.  
2) En relación a la contribución endógena del nicho de Células Madre Somáticas 
endometriales: 
Para ver la implicación de Lgr5 como posible marcador del nicho endógeno de 
Células Madre Somáticas endometriales, se emplearon secciones de endometrio a 
  
 
lo largo del ciclo menstrual para la identificación y localización de Lgr5, utilizando 
diferentes técnicas como son la hibridación in situ (a nivel de RNA mensajero), 
inmunohistoquímica y western blot (a nivel de proteína). El análisis de la longitud 
telomérica de las células Lgr5 determinadas por hibridación in situ permitirá 
establecer una primera aproximación como característica de célula madre. 
Finalmente, el aislamiento de esta población de células por citometría de flujo 
permitirá realizar experimentos in vivo para evaluar la formación de tejido 
endometrial humano en un modelo animal, como prueba de concepto.  
Conclusiones 
Las conclusiones extraídas de la presente tesis son: 
1. Las células XY procedentes de la médula ósea del donante son capaces de migrar 
al endometrio de la receptora, y transdiferenciarse a células estromales (expresan 
Vm), y células epiteliales (expresan CD9) contribuyendo a la regeneración del tejido 
endometrial. 
2. Las células XY derivadas del donante no son incorporadas en la población 
endometrial  Side Population (SP) considerada al menos en parte como la población 
de Células Madre Somáticas.  
3. Las células XY derivadas del donante no están asociadas con regiones de 
telómeros largos.  
4. Estas evidencias demuestran que las células XY derivadas del donante pueden  
ser consideradas como una fuente exógena temporal de células endometriales en 
lugar una fuente cíclica de Células Madre provenientes de la médula ósea.   
5. La expresión de Lgr5, determinada tanto a nivel de ARN mensajero como de 
proteína, está presente en el endometrio a lo largo del ciclo menstrual. Las células 
Lgr5 positivas se encuentran localizadas en la zona inferior de la capa funcional, 
cerca de la basal, estando en mayor frecuencia en el compartimento estromal. 
6. Algunas de las células Lgr5 positivas poseen telómeros largos, sugiriendo ciertas 
características de célula madre.  
  
 
7. La prueba de concepto de que Lgr5 es un marcador de Células Madre Somáticas 
endometriales se demuestra por la inyección de células Lgr5 positivas en la cápsula 
renal de un ratón NOD-SCID dando lugar a la formación de tejido endometrial 
humano.  
Como conclusión general, se demuestra que las Células Madre provenientes de la 
médula ósea contribuyen en la regeneración endometrial como una fuente 
exógena de células capaces de diferenciarse; mientras que Lgr5 puede ser 
considerado como un marcador del nicho endógeno de Células Madre 
endometriales. 
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I. INTRODUCTION 
1. Stem Cells 
1.1 Definition 
"Stem cells by definition are not terminally differentiated and have the ability to 
divide throughout the lifetime of the organism, yielding some progeny that 
differentiate and others that remain stem cells" (Alberts, 1989; Figure 1). 
 
Figure 1. Stem cells. Stem cells can regenerate themselves and produce specialized cell 
types (Image adapted from “Understanding stem cells: an overview of the science and 
issues” from the National Academies). 
1.2 Types and Classification  
Stem cells (SCs) are found from the early stages of human development to the end 
of the lifetime. There are different classifications for SCs based on their ability to 
differentiate (potency) or origin. Regarding their developmental potential, they can 
be distinguished as totipotent (capable of differentiating into a new organism), 
pluripotent (able to give rise to any cell type of the organism), or multipotent 
(giving rise to differentiated cells of the same embryonic lineage). Depending on 
their origin, SCs can be divided into five groups: embryonic stem cells (ESCs), 
primordial germ cells (PGCs), induced pluripotent stem cells (iPSCs), 
teratocarcinoma stem cells and somatic stem cells (SSCs), as shown in Figure 2. 
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Figure 2. Stem cell types depending on their origin. (Image adapted from Donovan and 
Gearhart “The end of the beginning for pluripotent stem cells”). 
1.2.1 Embryonic Stem Cells 
Embryonic stem cells (ESCs) were first isolated in 1998 by Thomson and Marshall 
from the inner cell mass of a human blastocyst. They possess the capacity to divide 
indefinitely whilst retaining their ability to make all cell types within the organism. 
However, their use for research presents legal and ethical problems which arise 
from their origin. 
According to Marshall et al. (2001) and Smith (2001) the defining characteristics of 
the ESCs are: 
 They can be obtained from the inner cell mass of a blastocyst, morula or 
even single blastomeres.  
 They have an unlimited capacity for asymmetric cell division, and remain 
undifferentiated in vitro in appropriate culture conditions.  
 They have a normal karyotype, which remains stable during the isolation 
and differentiation process. 
 They are able to differentiate into cell types of all three primary germ 
layers: ectoderm, mesoderm, and endoderm, as well as germ cells 
(gametes). This is the reason why they are termed pluripotent stem cells, 
which makes them a unique cellular type. 
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 In the murine model, when they are injected into a blastocyst they will 
form chimeras. 
 Injection of embryonic stem cells into an immunocompromised mouse 
gives rise to the formation of a benign tumour called a teratoma, which 
contains cellular components from all the three germ layers. 
 They express stem cell specific markers, including the transcription factor 
Oct-4, the Sex Determining Region Y-box2 (SOX2), and Nanog, which 
regulate a large number of genes, maintaining embryonic stem cells in a 
proliferating but undifferentiated state. 
1.2.2 Primordial Germ Cells 
Primordial germ cells (PGCs) are stem cells that give rise to gametes in vertebrates. 
During the early stages of embryogenesis, they originate outside the embryo and 
migrate by a well-defined route into the genital ridge. They are obtained from 
human embryonic gonadal ridge at 5-9 weeks of gestation and are the precursors 
of gametes (spermatozoa and oocytes). 
PGCs have biochemical, morphological, immunological, and developmental 
properties common to ESCs. They are pluripotent, and contribute to the formation 
of the germline when they are injected into blastocysts, giving rise to chimeric 
animals (Matsui et al., 1992; Stewart et al., 1994). PGCs can also differentiate into 
embryoid bodies and form teratomas in vivo. However, there are differences in the 
methylation pattern of these cell types that may reflect changes in the 
developmental program of the PGCs versus ESCs. However, the existence of this 
gene methylation pattern does not appear to affect the ability of these cells to 
contribute to germline development in chimeras (Sato et al., 2003). 
In primordial germ cell lines there is a great variability in the expression of genes 
that are subject to imprinting or gene regulatory mechanisms which modify their 
expression without changing their DNA sequences. As a consequence, in the 
offspring of chimeric mice resulting from injection of these cells, PGC genes are 
transmitted in a normal manner, while in other cases the animals show 
abnormalities in growth and bone structure. 
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1.2.3 Teratocarcinoma Stem Cells 
Teratocarcinoma is a type of malignant teratoma commonly found in the gonads 
but also occasionally in extra-gonadal sites, although the rate of spontaneous 
formation is very low (Fawcett, 1950). Teratomas are formed from malignant SCs 
called embryonal carcinoma cells which are regarded as equivalent to germ cells or 
early ESCs (Damjanov, 1993). They are pluripotent and therefore give rise to the 
multiple cell types found within them (Kleinsmith and Pierce, 1964; Stevens and 
Little, 1954), hence these tumours are composed of a haphazard mixture of 
somatic tissues and misshapen organs. 
The strain 129 mice showed an incidence of spontaneous testicular teratoma 
formation of 1%. The malignant nature of these tumours is displayed by their ability 
to quickly grow and invade when they are transplanted subcutaneously or 
intraperitoneally (Stevens and Little, 1954). 
Teratocarcinoma SCs retains their capacity to differentiate, producing derivatives of 
all three germ layers: ectoderm, mesoderm, and endoderm (Nicolas et al., 1976).  
Their properties include:  
 They possess the ability to participate in embryonic development resulting 
in chimeras. 
 The emergence of chromosomal aberrations. 
 The loss of differentiation capacity in culture. 
 In vitro differentiation only occurs under special conditions or using 
chemical inducers, and hence is much more limited. 
 The need for co-culture with feeder cells to maintain the undifferentiated 
state. 
1.2.4 Induced Pluripotent Stem Cells 
Induced pluripotent stem cells (iPSCs) are created by genetically reprogramming 
cells to become pluripotent stem cells. Yamanaka and colleagues first discovered 
the dedifferentiation of mouse somatic fibroblast cells to iPSCs in 2006, by the 
transfection of 4 genes. The key step in the discovery of the factors that enable cell 
dedifferentiation was the assumption that the transcription factors that maintained 
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the state of pluripotency in embryonic stem cells were the same as those that 
could induce dedifferentiation of somatic cells. The researchers tested 24 
combinations of transcription factors on somatic cells, and found that only four of 
them, Oct3/4, Klf4, Sox2, and c-Myc, were required to reverse cell differentiation 
(Takahashi K and Yamanaka S, 2006). 
The most important characteristics of iPSCs are: 
 iPSCs acquire a morphology similar to ESCs, such as the formation of 
colonies with a compact morphology, expression of pluripotency markers 
like Oct4, the ability to differentiate into cells of the endoderm, mesoderm, 
and ectoderm, and the ability to remain undifferentiated for long periods in 
culture. 
 In ESCs the CpG island promoters (regions devoid of methylation) required 
to express pluripotency genes are not methylated and thus the gene 
expression machinery has full access to these regions. In iPSCs cells these 
epigenetic marks are deleted, therefore allowing expression of previously 
silenced factors. 
 In addition, as embryos are not used, the ethical obstacles with ESCs are 
avoided. 
 The possibility of obtaining in vitro iPSCs opens a great number of 
applications in basic research as well as in the diagnosis and therapeutic 
implications for certain diseases.  
1.2.5 Somatic Stem Cells 
The primary function of somatic stem cells (SSCs; also named adult or progenitor 
stem cells) is to maintain tissue homeostasis by replenishing senescent or damaged 
cells after injury. SSCs are undifferentiated cells found among differentiated cells in 
any tissue or organ, which have the ability to self-renew and differentiate to result 
in tissue specific-cell types (Fuchs and Segre, 2000).  
The identification and characterization of these stem cells is one of the greatest 
scientific challenges that exists today. Their uniqueness, scarcity, and lack of 
distinctive morphological characteristics, such as defining cell surface markers, 
makes their identification and location a very complex task in most tissues.  
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Unlike ESCs, SSCs generally have a limited potency and are thought to give rise only 
to cells within the tissue of residence, or those from the same embryonic lineage. 
However, in recent years, evidence has accumulated that contradicts this dogma, 
suggesting that under certain circumstances these cells may `transdifferentiate´ 
and contribute to a much wider spectrum of differentiated progeny (Jiang et al., 
2002; Poulsom et al., 2001; Mezey et al., 2003). Transdifferentiation describes the 
conversion of a cell from one tissue lineage into a cell of a distinct lineage, with 
concomitant loss of the tissue-specific markers and function of the original cell 
type, and acquisition of markers and function for the transdifferentiated cell type.  
The suggestion that SSCs may transdifferentiate has given rise to the concept of 
stem cell plasticity, which holds that the lineage determination of a differentiating 
stem cell may not be rigidly defined, but is instead flexible, allowing these cells to 
respond to a variety of microenvironmental signals (Reyes, 2001; Wagers AJ and 
Weissman IL 2004). One of the most universal examples is that of hematopoietic 
stem cells (responsible for the formation of blood components), where both stem 
cells and their progeny, are capable of self-renewing and differentiating depending 
on the cell cycle phase and the microenvironment surrounding them (Quesenberry 
et al., 2005). 
Definitions and concepts 
SC self-renewal is the ability of one cell to produce identical daughter cells, and is 
essential for maintaining the SC reservoir in adult tissues.  
Asymmetric cell division is the mechanism implemented by these SSCs to produce a 
daughter cell identical to itself and a differentiated daughter cell (Figure 3). At the 
same time, stem cells also undergo symmetric divisions from progenitor cells, 
producing two daughter cells or transit amplifying cells (TA; Gargett, 2006). Finally, 
the differentiation process is driven by a change in cell phenotype due to 
expression of certain genes which would normally be associated with the cell 
function to which they are destined. 
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Figure 3. Hierarchical distribution of somatic stem cells. Stem cells are capable of self-
renewing and differentiating into committed progenitor cells. They proliferate and give rise 
to transient amplifying cells, which finally give rise to differentiated and functional cells 
without any further proliferation capacity (Image adapted from Chan et al., 2004). 
Role in tissue repair and regeneration 
SSCs are located in a physiological microenvironment called a niche, where they 
remain in a quiescent state mediated by signalling pathways that inhibit cell 
division and cell differentiation: among them, the transforming growth factor-β 
(TGF-β) and members of the family of bone morphogenetic proteins (BMP) (Li and 
Xie, 2005) are well known. SSCs play a key role in cellular homeostasis, promoting 
cell turnover in highly regenerative tissues, as well as cell loss by apoptosis (Snyder 
and Loring, 2005). 
It is undisputed that stem cells not only reside and function in tissues with 
exceptional regenerative capacity with a constant production rate of differentiated 
cells (e.g. bone marrow, intestine or epidermis), but that they also exist in low cell-
turnover tissues such as neural, retina, or kidney. In these tissues, the function of 
SSCs is likely the maintenance of cellular homeostasis through the re-organization 
of tissue when cells are lost by damage or apoptosis. After tissue damage or injury, 
the quiescent SSCs, re-enter in the cell cycle, resulting in the formation of TA cells, 
which undergo rapid proliferation and expansion cycles to allow tissue repair and 
replacement with fully differentiated and functional cells. Thus, SSCs maintain the 
I. Introduction 
10 
 
proper balance between cell turnover and the provision of a sufficient number of 
mature differentiated cells to maintain the proper function of tissues and organs. 
This balance between self-renewal and differentiation is regulated by the stem cell 
niche. 
1.3 The Stem Cell Niche Concept  
A cell niche is a physically located, structurally organized, and interactive unit that 
facilitates cell fate decisions in response to homeostasis in an appropriate spatio-
temporal manner. An intricate network of molecule and signalling pathways 
interactions all come together at the right place at the right time (Figure 4).  
 
Figure 4. Schematic representation of a stem cell niche. Niche cells direct the fate of 
somatic stem cells through cell signalling to initiate and/or block cell differentiation and cell 
cycle regulation (Image adapted from Spradling et al. “Stem cells find their niche”). 
These niches keep the SSCs in a quiescent state via molecular signalling pathways 
which inhibit cell division and differentiation. In the same way, they also facilitate 
the expansion and differentiation of stem cells when a necessity for tissue repair or 
regeneration arises. It is possible that these niches are constituted by endogenous 
SSCs that are resident inside the tissue. 
The concept of a stem cell niche was first proposed by Schofield in 1978 who 
hypothesized that the basic concepts that define a cell niche should be: 
1) In a location which is anatomically defined. 
2) A location where the stem cells can be maintained and reproduced.  
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3) A place where the differentiation process is inhibited.  
4) A limited space which also limits the number of stem cells.  
5) A place where reversion to a stem cell phenotype is induced at much 
slower rate than for a fully differentiated cell.  
This niche concept remained as hypothesis until 1998, when Xie and Spradling 
performed pioneering work in Drosophila melanogaster, showing that Schofield´s 
premises were true. This study demonstrated that germ stem cells in the fruit fly 
ovary reside adjacent to other cell types in a specialized location. This location is 
required for the preservation of the stem cell phenotype and produces specific 
signals, including the bone morphogenetic protein (BMP), capable of inhibiting 
differentiation. When contact with niche cells is lost, stem cells initiate their 
differentiation process. 
Niches have different characteristics in the different adult tissues depending on 
their cellular composition, structure, and location of the stem cells. Actually, 
numerous niches have been identified and characterized, such as the epidermal 
stem cell niche in the buldge follicle region (Fuchs et al., 2004), or the glandular 
crypts in small intestine (Booth and Potten, 2000). In the case of the small intestine 
niche, the crypt forms a pocket composed of epithelial cells at the base of the villi. 
Intestinal stem cells and TA cells continuously regenerate the villus crypt due to 
cellular loss in the normal digestive process over 3 to 5 days. There are 4 or 6 
intestinal crypt stem cells, which are located above the differentiated cells in the 
crypt base ring. The canonical Wnt signalling pathway regulates intestinal stem 
cells. This pathway triggers a specific program of gene expression through the 
stabilization and nuclear re-localization of β-catenin, while the signalling pathway 
triggered by BMP acts as a negative regulator of intestinal stem cell proliferation, 
exerting the opposite effect of Wnt. Many components of the signalling pathway 
are expressed inside the stem cell niche, such BMP-4, which is expressed in 
mesenchymal cells adjacent to intestinal stem cells; Noggin (a BMP inhibitor) which 
is expressed by intestinal stem cells and adjacent mesenchymal cells, meaning that 
transient Noggin expression inside the niche favours periodical activation of 
intestinal stem cells (Radtke and Clevers 2005). 
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2. Somatic Stem Cells in the Human Endometrium 
2.1 The Human Endometrium 
The human endometrium is the mucosal lining of the uterine cavity, whose basic 
function is to create a suitable environment for embryo implantation. It is 
hormonally regulated and undergoes periodical changes that underlie the 
menstrual cycle in humans and higher primates. These changes serve to prepare for 
the acquisition of the receptive state which is essential for embryo implantation 
and pregnancy.  
Histologically the endometrium is divided into two layers, a luminal level overlying 
the endometrial cavity and a functional layer formed by invagination of glands from 
the surface. All this forms the area called the `functionalis´ whereas the basal area 
`basalis´ is formed by the deeper glandular folds that reach the underlying smooth 
muscle wall, the myometrium (Figure 5). 
 
Figure 5. Anatomical and histological diagram representing the uterus. The uterus is 
formed by the myometrium (outer layer) and endometrium (inner layer). Cellular content in 
layers of endometrium, basalis, and functionalis are represented (Image adapted from the 
online reproductive database). 
It is known that the functional layer responds to progesterone and estradiol, 
exerting its action, through local mediators, over neighbouring cells in a paracrine 
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fashion, or over endometrial cells themselves in an autocrine pathway (Giudice, 
1994; Giudice et al., 2002), leading to shedding during menstruation. In contrast, 
the basal layer does not respond to steroid hormones and therefore does not shed, 
and is able to fully regenerate endometrium. 
The main cellular components of the endometrium are the epithelium, and the 
stromal and vascular components, in addition to the existence of a resident 
population of immune cells. 
_ Epithelium: A single-layer of prismatic epithelium that has three different types 
of cells: secretory, ciliated, and basal cells. Simple tubular uterine glands reach 
from the endometrial surface through to the base underlying the stroma-
myometrial junction. This monolayer regulates embryo implantation and controls 
the impact of the embryo on the endometrial stroma and blood vessels. With the 
exception of the basal fraction, this epithelium is shed during each menstruation, 
and is regenerated again in the next menstrual cycle.  
_ Stroma: A connective tissue composed of fibroblastic shaped cells and 
extracellular matrix. The main cell type present is the fibroblast, which is involved 
in extracellular matrix remodelling throughout the menstrual cycle and the process 
of decidualization. A portion of the stroma is also shed during menstruation and is 
regenerated in the same manner in the next cycle to re-form suitable conditions for 
embryo invasion.  
_ Endothelium and vascular smooth muscle: Intrauterine vascular architecture 
comprises an intricate network beginning in the myometrium. Uterine arteries 
extend into the spiral arteries, which are responsible for maintaining basal layer 
irrigation, and further branch into in the functional layer. 
_ Resident immune cells: The leukocyte population found in normal endometrium 
represents between 10-15% of the stromal cellularity. This population mainly 
consists of natural killer (NK) cells, macrophages, and T lymphocytes. The immune 
system cells are relevant for endometrial physiology, especially in the regulation of 
the local immune response to protect the genital tract from infections and to 
prevent immune rejection during embryo implantation.  
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The menstrual cycle 
During the menstrual cycle, the endometrium undergoes several changes in 
response to fluctuations in the levels of steroid hormones from the ovary. As a 
consequence of menstrual changes two phases can be distinguished: the 
proliferative and the secretory phase which are both separated by the ovulation 
process, (Figure 6). 
The proliferative or follicular phase, extends from the end of menstruation (day 
28/0) until ovulation (day 14). This is when the follicle containing the oocyte is 
developed, and a result an increased estrogen secretion is responsible for the 
proliferation of the endometrium (intensive mitosis in the glandular epithelium and 
stroma), the glands grow longer and the spiral arteries wind themselves lightly into 
the stroma when it reaches its greatest size. The endometrial thickness increases 
from 0.5-1 mm to about 7.5 mm (McLennan and Rydell, 1965). At the end of the 
proliferative phase an estradiol peak (released by the growing ovarian follicles) 
triggers a positive feedback mechanism at the level of the pituitary gland resulting 
in the commencement of ovulation 35 to 40 hours after the initial LH peak.  
 
Figure 6. Endometrial menstrual cycle. Changes occurring in the human endometrium 
during the different phases from both menstrual-ovarian cycle and hormone expression are 
shown (Image adapted from the online reproductive database). 
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The secretory or luteal phase, extends from the moment of ovulation (day 14) to 
menstruation (day 28/0). The progesterone concentration increases because the 
corpus luteum secretes and maintains high estrogen levels. Progesterone limits the 
proliferative effect of estrogens on the endometrium and promotes differentiation, 
glandular secretion of glycogen, and glycoproteins, and stromal decidualization. 
Furthermore, growth of endometrial blood vessels continues, acquiring a tortuous 
appearance. All these changes prepare the endometrium for its receptive stage. In 
the absence of embryonic implantation, the corpus luteum degenerates and 
therefore the levels of ovarian hormones (estrogen and progesterone) drop 
dramatically causing involution and shedding of the endometrium. 
There are several pathologies associated with the endometrium. Endometriosis is 
an estrogen-dependent disease defined by the growth of endometrium outside its 
physiological niche, whereas in endometrial cancer malignantly transformed cells 
are only linked to hormonal changes in some cases. In the case of Asherman´s 
syndrome there is a complete destruction of the uterine cavity because of the 
formation of adherences resulting in infertility and amenorrhea. 
2.2 Existence of Somatic Stem Cells in the Human Endometrium  
Preliminary evidence 
The human endometrium is a tissue with an exceptional capacity for regeneration, 
since it is able to undergo more than 400 cycles of regeneration, tissue 
differentiation, and shedding over the female reproductive life. On a monthly basis, 
and under the influence of circulating estrogen, the endometrium undergoes 
growth ranging from 0.5-1 mm to 5-7.5 mm. 
This evidence led to Prianishnikov and Padykula (Prianishnikov, 1978; Padykula et 
al., 1984, 1989) to speculate the existence of SSCs in the endometrium. They 
described that the endometrium undergoes regression in menstruating primates as 
a result of the loss of the functional layer. Classical morphological studies divide the 
endometrium into four zones: Zone I, which consists of luminal epithelium and 
underlying stroma; Zone II which includes previous cellular components as well as 
the microvasculature (Zones I and II are associated with the functional layer); Zones 
III and IV consist of basal segment glands and stroma associated with the basal 
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layer. Thus, after the menstrual cycle, Zones III and IV remain intact and 
occasionally some fraction of Zone II may persist. In this context, in the early 80s, 
the existence of a SSC population residing in Zones III and IV was suggested, with 
TA cells in Zones II and III and differentiated cells in Zones II and I, as shown in 
Figure 7. 
 
Figure 7. Human endometrium and somatic stem cells. Left panel: distribution of the 
endometrium divided into four zones as described by classical studies. Zone I (luminal 
epithelium and subjacent stroma) and zone II (luminal epithelium, stroma, and 
microvasculature) are associated with the functionalis layer. Zones III and IV consist of basal 
segments of glands and stroma associated with the basalis layer. Right panel: hierarchical 
organization of stem cells in adult tissues showing the putative location of the stem cell 
niche (zones III and IV), transit amplifying cells (zones II and III), and differentiated cells 
(zones II and I) in the human endometrium. Abbreviations: SC (stem cell), TA (transit 
amplifying cell), DC (differentiated cell). 
In 2004 a descriptive study by Cho and collaborators analyzed the presence of two 
stem cell markers (c-Kit/CD117 and CD34) in human endometrium from the fetal to 
the postmenopausal period. CD117, a cell surface marker for hematopoietic stem 
cells and germ cells, and plays an important role in cell differentiation and 
proliferation. CD34 is the most common marker for hematopoietic stem cells 
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(defined as multipotent stem cells that give rise to all blood cell types). The 
expression of both markers in the human endometrium by immunohistochemistry 
suggests the presence of cells with stem cell features in the endometrium at the 
different periods analyzed. In addition, these cells appear mainly in the stromal 
compartment of the basalis layer and thus avoid cyclic shedding due to 
menstruation (Cho et al., 2004). Another innovative publication explored the 
involvement of bone marrow stem cells (BMSCs) in endometrium. Molecular 
analyses of endometrium in four bone marrow transplant (BMT) recipients 
demonstrated the presence of donor-derived bone marrow cells in both the 
epithelial and stromal compartments of the newly formed endometrium, implying 
the possibility of BMSCs as a new ectopic source of endometrial SSCs (Taylor et al., 
2004). 
Clonogenic cells 
The first evidence for SSC activity in human endometrium was produced by 
demonstrating that single cells proliferate and produce individual colonies in 
culture. Gargett´s group (Chan et al., 2004; Schwab et al., 2005) identified small 
populations of these colony forming units (CFUs) in freshly isolated cells from the 
epithelium and stroma which comprised 0.22% and 1.25% of the total cell 
population and were EpCAM positive or negative respectively. 
Both cell fractions gave rise to colonies of different sizes. In the case of epithelium, 
the large CFUs differentiated in vitro into gland-like structures (which were 
cytokeratin+), while the large CFUs from stroma exhibited multipotent features. 
Stromal CFUs with an appropriate differentiation treatment were able to 
differentiate in vitro into muscle cells, adipocytes, osteocytes, and chondrocytes 
hence showing a mesenchymal stem cell (MSC) phenotype. By contrast, the small 
colonies had a limited proliferative capability. Characteristics of self-renewal, such 
as a high proliferative potential, and a high differentiation capacity in culture 
conditions supported that these cells exhibit key SSC features.  
Endometrial stem cell phenotypes 
Several markers for human endometrial SSCs have been described, although no 
agreement on them has been reached. Gargett and collaborators described the co-
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expression of two specific markers, CD146 and PDGF-Rβ in CFU stromal cells 
(Schwab and Gargett 2007). This CD146+ PDGF-Rβ+ cell population was multipotent, 
showing differentiation toward typical mesodermal lineages; it also showed typical 
expression of MSC markers and was located near blood vessels in both the basal 
and functional layer, and expressed typical pericyte markers and genes related to 
angiogenesis. 
Another endometrial stem cell population described is characterized by the marker 
W5C5 (Masuda et al., 2012), which purifies a stromal population similar to the 
CD146+ PDGF-Rβ+ population. To date there have been no reported markers for 
endometrial epithelial stem cells.  
Menstrual blood progenitor cells  
Menstrual blood is being studied for endometrial stem cell research. It is 
hypothesized that endometrial SSCs, at least in part, may be discarded during 
menstruation (Gargett and Masuda 2010). After collection of menstrual blood, 
endometrial cells are isolated and cultured where they acquire an appearance 
similar to fibroblasts and have a high proliferative potential (Hida et al., 2008; 
Meng et al., 2007; Patel et al., 2008). Additionally these cells display telomerase 
activity and typical phenotypic MSC markers (Cui et al., 2007; Hida et al., 2008; 
Meng et al., 2007; Patel et al., 2008). Studies show that these cells exhibit an ability 
to differentiate in vitro into typical mesodermal lineages, and also into 
cardiomyocytes and skeletal muscle (Cui et al., 2007; Hida et al., 2008), in addition 
to neurons of ectodermal lineage (Patel et al., 2008). The presence of stromal cells 
but not epithelial cells in menstrual blood, suggests that epithelial progenitors must 
reside in the basal endometrium and are not released during menstruation (Musina 
et al., 2008). In fact, menstrual blood cells have been reprogrammed into a 
pluripotent status and differentiated into various cell types from all 3 germ layers 
both in vitro and in vivo (Li et al., 2013). 
2.3 Side Population Isolation as a Method to Identify Somatic Stem Cells in 
Endometrium  
A widely used approach to identify SSCs is the search for the side population (SP) 
cells in a particular tissue or organ; the first work done using this methodology was 
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described by Goodell for bone marrow. It is based on the use of a fluorescent vital 
dye called Hoechst 33342, which specifically binds to adenine-thymidine rich 
regions in the double DNA chain. Undifferentiated cells are enriched in ABC 
multidrug resistance membrane transporter proteins which are responsible for the 
expulsion of Hoechst (Goodell et al., 1996). Accordingly, undifferentiated cells are 
able to efflux Hoechst in the short term. These SP cells separate as a discrete 
population when viewed on a lateral two-colour diagram on a flow cytometer. 
Several groups have identified and characterized SP cells in the human 
endometrium. In 2007, Kato described the first work on the SP phenotype of 
endometrial cells, which mainly had a CD13- and CD9- phenotype, distinguishing 
immature endometrial cells and progenitor cells. In culture these SP cells were 
capable of producing gland-like structures (CD9+) and stromal cells (CD13+; Kato et 
al., 2007). Moreover in 2008, Tsuji et al. analysed the endometrial SP population as 
a heterogeneous mixture of cells expressing typical stromal cell markers such as 
CD13, CD31 and CD34 (endothelial), the epithelial cell marker (EMA) and CD146 
and CD105 (mesenchymal), as well as also being negative for CD45 (hematopoietic 
lineages). The SP phenotype was correlated at the molecular level with a high 
expression of ABC protein type BCRP1/ABCG2, which was located in the basal area 
of the endometrium. In addition, these SP cells had a high colony formation in vitro 
(Tsuji et al., 2008). 
In 2010, two independent groups finally performed a xenograft of SP cells in NOD-
SCID mouse model as a functional proof of the concept of endometrial SSCs 
(Cervelló et al., 2010; Masuda et al., 2010). Our group (Cervelló et al., 2010) 
isolated SP cells from both cell fractions, epithelium and stroma, with SP 
representing 1.6% and 0.3% of the original cell samples respectively. The cellular 
purity of each fraction was assessed by phenotypic analysis, CD9 in the case of 
epithelium and Vimentin (Vm) in the case of stroma. Immunophenotypic analysis of 
SP cells revealed that they were around 70-80% positive for CD90, only 1-2% cells 
were positive for CD34, and 5-7% were positive for CD45. These results suggest 
that, as expected epithelial and stromal SP cells have a mesenchymal and not a 
hematopoietic phenotype. In addition at the molecular level, expression of certain 
SC markers was analysed: interestingly SP cells were enriched for c-KIT and OCT-4 
as well as markers of ABC membrane transporters, MDR1, and BCRP-1.  
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SP cells showed an intermediate telomerase activity pattern which was between 
that of human ESCs and non-side population (NSP) cells as differentiated cells. 
Clonal efficiency was tested in hypoxic culture conditions, where SP cells showed a 
much higher capacity to form colonies than NSP cells, although the differences 
were statistically significant only in the case of the stromal fraction. A genetic 
signature for endometrial SP cells common in epithelium and stroma was also 
generated using microarrays, identifying a total of 44 upregulated and 14 
downregulated genes. 
 
Figure 8. Formation of human endometrium-like tissue after subcutaneous injection of SP 
cells in NOD-SCID mice. Immunohistochemical analysis for human Progesterone Receptor 
together with the existence of two amplicons for GAPDH corresponding to different species 
(human and mouse) allowed the detection of the newly formed endometrial-like tissue 
(Image from Cervelló et al., 2010).  
I. Introduction 
21 
 
To determine whether SP cells were clear stem cells candidates, a differentiation 
assay was performed in vitro and in vivo as a proof of concept of multipotentiality; 
they were differentiated into adipocytes and osteocytes, and formed 
endometrium-like structures after injecting them subcutaneously in NOD-SCID 
mice, respectively. As a result it was shown that endometrial SP cells exhibit 
genotypic and phenotypic features as well as the functional capacity to develop 
human endometrium after injection into NOD-SCID mice. 
Independently, Masuda and collaborators obtained a similar percentage of SP cells 
from the endometrium which exhibited predominantly endothelial markers. SP 
cells proliferate in vitro and differentiate into various types of endometrial cells, 
including glandular epithelial, stromal and endothelial cells. Furthermore, SP cells 
were able to reconstitute human endometrial tissue with well-delineated glandular 
structures when they were transplanted under the kidney capsule of 
immunodeficient mice. In these endometrium-like structures, mature blood vessels 
were formed de novo, showing the potentiality of SP cells for angiogenesis and 
endometrial cell regeneration in vivo (Masuda et al.,2010). 
Our group generated seven human endometrial SP cell lines (ICE 1-7; Cervelló et al., 
2011): four from the epithelial and three from the stromal fraction, respectively. 
Briefly, SP cell lines were generated following selection of individual large colonies 
that grew in culture under hypoxic conditions for 12-15 passages. The lines showed 
a normal 46XX karyotype, an intermediate telomerase activity pattern, and were 
enriched in stem cell markers such as Oct-4, GDF3, DNMT3B, Nanog, and GABR3 as 
well as mesodermal markers like WT1, Cardiac Actin, Enolase, Globin, and REN. The 
stromal or epithelial phenotype was confirmed by the expression of specific 
markers, CD9 in the case of epithelium, and Vm in the case of stroma. Surprisingly, 
the cell lines did not express estrogen (ERα) or progesterone (PR) receptors 
suggesting that they were undifferentiated of some degree. Furthermore these 
lines were able to differentiate in vitro into adipocytes and osteocytes, which 
confirmed their mesodermal origin. Finally, they were able to generate 
endometrial- like tissue when they were transplanted into the kidney capsule of 
NOD-SCID mice. These findings confirm that SP cells exhibit key properties of 
endometrial SSCs and open new possibilities for understanding gynaecological 
disorders such as endometriosis or Asherman's syndrome (Cervelló et al., 2011).  
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3. Putative Markers and the Origin of Human Endometrial Somatic Stem Cells 
3.1 Searching for Endometrial Stem Cell Markers 
Searching for specific endometrial SSC markers is one of the major objectives in the 
field of reproductive and regenerative medicine, and a lot of work has attempted 
to elucidate novel endometrial stem cell markers.  
Musashi-1 is an RNA binding protein that is associated with the maintenance and 
asymmetric cell division of epithelial and neural progenitor cells (Okano et al., 
2005). In a broad study, mRNA expression levels of Musashi-1 were determined in 
both epithelial and stromal cells, and were higher in the proliferative versus 
secretory endometrium with even more pronounced expression in the basal 
region. Furthermore, a greater percentage of cells positive for Musashi-1 were 
found in both endometrial carcinoma and endometriotic tissue compared with 
normal endometrium, suggesting a possible origin based on the activity of stem 
cells in endometriosis and endometrial carcinoma (Gotte et al., 2008). 
Other work, reported a sub-population of endometrial cells in the stromal 
compartment which co-expressed the markers CD146 and PDGF-Rβ, and was 
characterized as having MSC properties, CFU activity, and also the ability to 
differentiate in vitro into fat, muscle, cartilage, and bone tissues (Schwab et al., 
2007). The same group used a panel of antibodies to identify perivascular markers 
in stromal cells. Among them, W5C5 was particularly effective in selecting 
endometrial mesenchymal stem-like cells (eMSCs). These W5C5+ cells comprised 
about 4.2% of the endometrial stromal cells and resided predominantly in a 
perivascular location in both the basal and functional layers of the endometrium. 
W5C5+ cells are related to the existing eMSC markers PDGF-Rβ and CD146: most 
W5C5+ cells expressed PDGF-Rβ, while all the W5C5+CD146+ cells were positive for 
PDGF-Rβ. Despite this, W5C5+ cells showed even greater clonogenicity and were 
able to differentiate in vitro into adipocytes, osteocytes, chondrocytes, myocytes 
and endothelial cells. After injection of these cells into the mouse kidney capsule, 
W5C5+ cells produced endometrial stromal-like tissue in vivo, thus identifying W5C5 
as a putative marker of endometrial mesenchymal stem-like cells (Masuda et al., 
2012). 
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It has also been reported that Wnt family members play an important role in the 
female reproductive tract. During embryonic development, there is a gradual 
expression of different Wnt molecules such as Wnt4, Wnt9b, Wnt7a and Wnt5a in 
the Müllerian ducts, which are responsible for setting the proper formation of the 
uterus, cervix and vagina. Therefore a key role for this signalling pathway in the 
endometrium has been hypothesized (Tulac et al., 2003). 
Endometrial gene expression studies conducted throughout the menstrual cycle 
phases revealed that some of the Wnt molecules were upregulated by estrogen 
during the proliferative phase, while in the secretory phase, progesterone acted as 
an activator of the Wnt pathway inhibitors (Wang et al., 2010). Thus, ovarian 
steroids regulate the Wnt pathway in the endometrium, maintaining a balance 
between estrogen-induced proliferation and progesterone-guided differentiation 
(van der Horst et al., 2012). Furthermore, differential Wnt expression pathway 
between pre- and post-menopausal endometrial epithelial cells suggests that an 
epithelial stem cell population resides in the basalis layer (Nguyen et al., 2012). All 
these studies indicate that somatic stem cells play an important role in the 
regeneration of the endometrium and that the Wnt signalling pathway is involved 
in their maintenance. 
Accumulated evidence based on lineage tracing studies indicates that a surface 
protein named Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) 
is a marker that can identify SSCs in several tissues such as small intestine mucosa 
(endodermal origin; Barker et al., 2007), hair follicles (ectodermal origin; Jaks et al., 
2008), and mature kidney nephrons (mesodermal origin; Barker et al., 2012). This 
protein plays a crucial role in the Wnt/β-catenin signalling system by acting on the 
self-renewal and maintenance of the SSC population. All these data suggest the 
possibility that Lgr5 could be considered a universal SSC marker (Schuijers and 
Clevers 2012). 
Lgr5 molecule expression in human endometrium was first described in 2007 by 
Krusche and colleagues, a publication which coincided with Clevers’ identification 
of this protein as a SSC marker in the small intestine and colon. Krusche et al. 
demonstrated constitutive Lgr5 expression at the mRNA level throughout the 
menstrual cycle and interestingly, this expression was higher in endometrial 
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epithelial cells compared to stromal cells and was not hormonally regulated 
(Krusche et al., 2007). 
 
 
Figure 9. Proposed model for Lgr5 expression by small intestine cells. Expression of LacZ-
Lgr5 cells (shown in blue) in adult mouse tissues: small intestine and colon. In both cases 
expression is confined to a few cells located at the crypt base (Adapted from literature 
published by Clevers et al.). 
Sun and collaborators demonstrated that Lgr5 expression in the mouse uterus was 
dynamic and dependent on the developmental stage of the uterus. Indeed, the 
influence of ovarian hormones in the oscillation of Lgr5 expression revealed that in 
the presence of estrogen and progesterone, its expression decreased. Furthermore, 
Lgr5 expression was undetectable in the absence of β-catenin in lacZ reporter mice 
(Sun et al., 2009). Despite these findings, the function and regulation of the Lgr5 
gene in the uterus remains largely unknown. 
3.2 Implication of the Bone Marrow as an Exogenous Contributor to the SSC pool 
Bone marrow derived stem cells (BMSCs) include many populations of progenitor 
cells: hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) or stromal 
cells, side population (SP) cells, and multipotent adult progenitor cells (MAPCs) 
(Dimmeler et al., 2005). 
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BMSCs administered after minimal manipulation, represent an important cell 
source for cell-based therapies. It is known that BMSCs have the ability to 
differentiate in vitro into multiple non-hematopoietic cell types (Pittenger et al., 
1999; Mezey, 2011). Furthermore, it has been shown that in human patients 
undergoing bone marrow transplant (BMT), cells from the donor were able to 
differentiate into multiple cell types, as a result producing chimeric organs. Cases of 
transdifferentiation into hepatocytes (Theise et al., 2000), neurons (Mezey et al., 
2003), cardiomyocytes (Quaini et al., 2002), and skin (Korbling et al., 2002, Nemeth 
et al., 2012) have been reported, where bone marrow donor cells migrate to the 
recipient organ and repair damaged tissues. The percentages of chimerism were 
about 2% to 8% in the case of keratinocytes, depending on the clinical trial. 
Nonetheless, there is no doubt that circulating cells from bone marrow can reach 
the skin and participate in its regeneration under non-pathological conditions, for 
example, the toxicity of chemotherapy results in hair loss which requires stem cell 
mediated regeneration (Nemeth et al., 2012).  
It has been postulated that this repair can involve one or more of the following 
mechanisms (Mezey, 2011; Figure 10): 
1) BMSCs (like HSCs), would be induced to enter into circulation through the 
bloodstream, or after being injected locally at the site of damage or injury. These 
cells become tissue-specific stem cells, proliferating and regenerating the tissue. 
2) BMSCs may enter into organs, secreting paracrine factors that induce 
proliferation and/or differentiation of tissue-resident somatic stem cells. 
3) BMSCs would secrete anti-apoptotic factors from the injured tissues to allow 
survival of damaged cells. 
4) BMSCs could regulate the function of the immune system by inducing or 
inhibiting specific pathways for cytokine production. 
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Figure 10. Possible mechanisms implemented by bone marrow stem cells to differentiate 
into other cell types. Tissue repair might involve one or more of the mechanisms 
summarized above. Adapted from Mezey “The therapeutic potential of bone marrow-
derived stromal cells”. 
HSCs are capable of giving rise to all the different types of blood cells (myeloid, 
erythroid, lymphoid, mast cells, and platelets); whereas MSCs have the potential to 
differentiate only towards lineages of mesenchymal origin, including bone, 
cartilage, fat, connective tissue, smooth muscle, and hematopoietic supportive 
stroma (Pittenger et al., 1999). MSCs usually express CD73, CD90, and CD105 
antigens and lack expression of the major histocompability complex (MHC) class II 
surface molecules, and endothelial (CD31) and hematopoietic (CD34, CD45, CD14) 
specific antigens (Dominici et al., 2006).  
In 2002, Verfaillie´s group described the derivation of rare cells from rat and mouse 
bone marrow (BM) with characteristics different from most adult stem cells. These 
cells, termed MAPCs, could proliferate without becoming senescent and could 
differentiate in vitro at the single cell level into cells of the three germ layers (Ulloa-
Montoya et al., 2007). This remarkable differentiation potential makes this 
particular subset of cells a candidate for tissue transplantation. 
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Studies in murine endometrium  
The origin of endometrial SSCs remains unclear, although tissue specific somatic 
stem cells from endometrium have been described (literature cited above), an 
alternative source could be the bone marrow itself, either continuously or in 
specific circumstances. 
To address this issue, the murine endometrium has been studied. In 2007, Taylor 
designed a male to female BM transplant model to demonstrate that BM derived 
stem cells can engraft the endometria, as Y chromosome endometrial cells were 
found in the uterus of transplanted mice. This fact suggests two important points: 
first, BM-derived cells can generate endometrium, thus proving their mesenchymal 
origin, and second, that they have a role in tissue repair after injury (Du and Taylor, 
2007). However, their contribution to cyclic endometrial functions is reduced, 
which might be due to the irradiation used prior to BM transplantation which 
compromises fertility. 
BMSCs are largely comprised of: HSC and MSC populations, although which BMSC 
subpopulation promotes endometrial reconstruction remains unresolved. In an 
attempt to address this issue, Bratincsak used transgenic mice to determine 
whether CD45 progeny contribute to repopulation of uterine epithelium in healthy 
conditions. Females were examined throughout adult life and stromal and 
epithelial cells from CD45 progenitor cells were observed; in the case of epithelium 
the percentage increased in relation to number of oestrous cycles (Bratincsak et al., 
2007). Conclusions from these studies led to the hypothesis that circulating HSCs 
might enter into the stroma, and when they are needed enter into the epithelium 
to regenerate it.  
The involvement of the HSC pool per se has also been described by Du in 2012, 
where HSCs were mobilized using the granulocyte colony stimulating factor (G-
CSF), as a potent cytokine that regulates granulopoiesis. After induced ischemia 
followed by BMT, mice received G-CSF; at 8 months follow-up it was understood 
that this cytokine did not increase BMSC migration to the uterine endometrium, 
and in fact this treatment resulted in significantly lower stem cell recruitment to 
the uterus (Du et al., 2012). This report also addresses the important question of 
whether BMSC physiologically contribute to the uterus or just participate in repair 
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tasks after injury. In fact, the induced ischemia resulted in recruitment of 
approximately 2-fold more stem cells to the endometrial stroma, but not to the 
epithelium, indicating that the stroma is the main target of injury. Additionally, 
injury may be more important in mobilization of BMSCs to endometrium than 
hormonal signals because even when ovarian function is restored after injury 
migration of more BMSCs to endometrium is not induced (Du et al., 2012). 
Studies in human endometrium  
In the first study published describing the human endometrium following BMT, the 
Taylor laboratory demonstrated the existence of circulating stem cells of extra-
uterine origin that could differentiate into endometrial tissue. BM-transplanted 
women were recruited in a clinical trial where donors and recipients were female 
with different human leukocyte antigen (HLA) phenotypes. The mismatched HLA 
type for each donor-recipient pair allowed the origin of the cells to be determined. 
A greater number of donor-derived stromal cells compared to glandular epithelial 
cells were found, suggesting a differential rate of transdifferentiation (in all cases 
derived donor cells were CD45 negative). Furthermore, the percentage of donor 
cells depended on the length of time from treatment to biopsy, as well as multiple 
factors including chemotherapy regimen, radiation dosage, graft versus host 
disease and other endometrial conditions unrelated to the transplantation (Taylor, 
2004).  
In 2007, flow cytometry analysis revealed a phenotypic population of HSCs in the 
endometrium of healthy women. This population was CD45+ and CD34+, but 
different from the HSC population in BM due to low c-kit expression and expression 
of committed lymphoid progenitor markers (Lynch et al., 2007).   
A few years later, Mints and Cols extended this knowledge, focusing their study on 
endothelial progenitors, indicating that these progenitor cells from bone marrow 
could also contribute to the formation of new endometrial blood vessels, 
expressing both CD34 and VEGFR2 markers, in a process known as angiogenesis 
(Mints et al., 2008). 
Another original approach, using a sex-mismatched donor-receptor system (Ikoma 
et al; 2009), showed the formation of endometrium from male donor cells, 
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resulting in both epithelial and stromal cells, as assessed by the expression of the 
typical markers cytokeratin and CD10, and negative expression for CD45. However, 
the percentage of cells coming from the donor were less than those reported by 
Taylor (2004), suggesting a lower efficiency or ability of male cells to form female 
reproductive organs. Surprisingly, the percentage of donor-derived cells was 
greater in stroma than epithelium, and in contrast to previous studies, there was 
no significant correlation between the time from transplantation to biopsy and the 
percentage of donor-derived cells present. A specific hematopoietic stem cell 
contribution to the endometrium has also been described, although patients 
receiving hematopoietic progenitors did not show donor chimerism between 
stromal and bone marrow cells, indicating that these cells do not contribute to the 
endometrial stem cell pool (Wolff et al., 2012). 
Together these reports recognise the contribution of bone marrow to endometrial 
regeneration, but do not define the specific subpopulation of cells making the 
contribution, since unfractioned bone marrow cells were used. 
The existence of a circulating source for endometrial SSCs might represent an 
alternative theory to explain the etiology of endometriosis, especially in the case of 
endometriotic foci which present outside the peritoneal cavity, such as in lung or 
brain (Du and Taylor, 2007). 
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II. HYPOTHESIS 
The hypothesis of this project is that human endometrial stem cells are produced 
from endogenous and exogenous sources and the main questions to be answered 
are:  
1. Can bone marrow derived cells contribute to the endometrial somatic stem cell 
reservoir or do they transdifferentiate into endometrial cells?  
2. Is Lgr5 a universal marker for somatic stem cells and can it identify the 
endogenous endometrial stem cell niche?  
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III. OBJECTIVES 
The primary objectives of this thesis are: 
1. To demonstrate the contribution of BM as an exogenous source of cells 
for the endometrial stem cell niche. 
2. To investigate the Lgr5 marker to identify the endometrial endogenous 
stem cell niche.  
 
The secondary objectives of this thesis are: 
1.1 To identify the Y-chromosome bearing cells in the human endometrium 
and phenotype them. 
1.2 To analyse the telomerase length of endometrial cells in BM 
transplanted recipients. 
1.3 To investigate the contribution of BM to the side population cell cohort 
in BM transplanted patients.  
2.1 To investigate the presence of the Lgr5 marker in endometrium 
throughout the menstrual cycle.  
2.2 To correlate the Lgr5 mRNA-expressing cells with their telomere length 
as criteria to assess their `stemness´.  
2.3 To isolate the endometrial Lgr5 positive cells and inject them into the 
kidney capsule of NOD-SCID mice in order to assess endometrial-like tissue 
reconstruction. 
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IV. EXPERIMENTAL DESIGN 
We established the following study design: 
 
1) Exogenous contribution to the endometrial stem cell reservoir 
 
To analyse the contribution of BM to endometrial regeneration we created a BM 
transplant model in which the donor-recipient pair were sex mismatched, making it 
possible to distinguish contribution of bone marrow cells by the presence of Y 
chromosome-bearing cells using fluorescent in situ hybridization. The phenotype of 
these cells will be assessed with specific markers such as CD45, CD9, and Vimentin. 
The analysis of telomere length will be performed using telomapping and 
evaluation of the side population cells as an endogenous pool of stem cells in the 
recipient endometrium will allow us to determine the contribution of BM, and may 
enable correlation with the different sources of stem cells. 
 
 
2) Endogenous contribution to the endometrial stem cell niche 
 
To assess the implication of Lgr5 as a marker for the endogenous endometrial stem 
cell niche, endometrial sections will be used to identify and locate Lgr5 using 
different techniques such as in situ hybridization, immunohistochemistry, or 
western blotting.  
The analysis of telomere length associated with Lgr5 expression by in situ 
hybridization will serve as an approximation of the stemness features of these cells. 
Finally, the isolation of this population by flow cytometry will allow us to perform in 
vivo proof of concept experiments to assess whether these cells will form human 
endometrium as a xenograft in an animal model. 
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V. MATERIALS AND METHODS 
5.1. Exogenous Contribution of the BM to the Human Endometrial Stem Cell 
Niche 
The use of human biological samples in this project was approved by the 
institutional review board of the Hospital Universitario La Fe registered under law 
number 2009/0364. Samples were obtained after the project was explained and 
with written informed consent from all cases (see Annex I). 
5.1.1 Biological Samples  
Five female patients were enrolled in this study; they received allogeneic BM stem 
cell transplantation from male donors for the treatment of haematological 
malignancies at the Haematology Department, Hospital Universitario La Fe, 
Valencia, Spain, from May to October 2010. The epidemiological and oncological 
characteristics of the transplanted patients are presented in Table I. 
Table I. Epidemiological and oncological characteristics of the BM-transplanted recipients. 
*Endometrium from patient 5 was evaluated as atrophic. 
-  The recipients’ ages ranged between 28 and 41 years. 
- Patients presented a variety of haematological malignancies: chronic myeloid 
leukaemia (CML) in two patients (patients 1 and 3); acute myeloblastic leukaemia 
(AMbL) in two patients (patients 2 and 5); and acute lymphoblastic leukaemia (ALL) 
in one patient (patient 4). 
- All the patients received a busulfan based myeloablative conditioning regimen 
without total body irradiation (TBI). Patients 1, 2 and 5 received transplantation 
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from unrelated donor umbilical cord blood (UD-UCB). Patient 3 received an HLA-
(human leukocyte antigen)-matched unrelated bone marrow transplant (UD-BMT). 
Whereas patient 4 was transplanted using mobilized peripheral blood stem cells 
(PBSC) from an HLA-matched sibling donor. 
- Patients with secondary amenorrhea after transplantation received hormone 
replacement therapy (HRT) using a gonadotropin-releasing hormone agonist 
(GnRH-a; Decapeptyl 3.75, IPSEN, France) injected on day 21 of the previous cycle. 
Hormones received were estradiol valerate (EV; Progynova; Schering Spain, 
Madrid, Spain), at 6 mg daily, initiated on day 2 of the cycle for at least 10 days, 
while progesterone (Utrogestan, Corne, Mexico), 800 mg per day, was added as 
previously described (Reis et al., 2012; Soares et al., 2005). Endometrium from 
patient 5 was evaluated as atrophic. 
Collection and processing of biological samples 
Endometrial tissue specimens were obtained using a Pipelle catheter (Gynetics 
Medical Products N.V, #4164 probet, Belgium) under sterile conditions from the 
uterine fundus at a minimum of 4 months after starting HRT. The tissue was 
collected immediately after the extraction and was kept in phosphate buffered 
saline (PBS) until its processing.  
Endometrial samples were then washed with PBS to remove mucus and blood 
traces. Biopsies from all five bone marrow transplanted (BMT) recipients were 
processed as formalin-fixed paraffin-embedded tissues and were also digested 
enzymatically in order to obtain viable single cells. The main part of the sample 
(two-thirds) was subjected to an epithelial and stromal cell separation protocol, 
and the remainder was fixed in 4% paraformaldehyde (PFA) and paraffin-
embedded. 
5.1.2 Isolation of Side Population Cells 
5.1.2.1 Epithelial and Stromal Cell Separation from Human Endometrial Biopsies 
All cellular procedures were carried out in sterile conditions to avoid contamination 
by external agents. Thus, sample collection and processing was done with sterilized 
material in a laminar flow hood in an aseptic area of the culture laboratory.  
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Epithelial and stromal cell fractions were isolated using an established protocol 
(Simón et al., 1993) with minor modifications. Samples were carefully dissected and 
minced into 1-2 mm3 fragments. After mechanical disaggregation, enzymatic 
digestion was carried out with collagenase type IA at 10 mg/mL (Sigma-Aldrich, 
Spain) diluted in DMEM (Dulbecco´s Modified Eagle Medium; Sigma-Aldrich, Spain) 
at a final concentration of 10 mg/mL. Following this, sample was left at 4° C 
overnight (ON). Collagenase is an enzyme that hydrolyses collagen in its triple-
helical conformation, releasing small tissue fragments and isolated cells. 
After this, both fractions: stromal and epithelial cells were separated on a size-basis 
protocol using gravity sedimentation and membrane filtration. Disaggregated cells 
were stored vertically for 10 min after vigorous agitation, as a result a pellet with 
epithelial cells was formed, making it possible to take the supernatant (stromal 
cells) and pass it into a new tube; this procedure was repeated twice. The large-size 
cells tend to sediment faster to the lower part of the tube and correspond with 
gland and epithelial cell fragments, while the smaller stromal cells remain in the 
upper part. 
Cellular suspensions corresponding to stroma were filtered through 30 µm filters 
(Partec, Celltrics) and centrifuged at 580 g for 7 min. The supernatant was 
discarded and DNase (Sigma-Aldrich, Madrid, Spain) was added to the pellet, in 
order to eliminate the free DNA resulting from cellular lysis that favours the union 
of cells like a network. Due to high content of blood in the stroma, cell suspension 
was treated for 5 min at room temperature (RT) with erythrocyte lysis solution, 
eliminating blood cells by hypotonic shock (1.5 M NH4Cl, 100 mM NaHCO3, and 
Ethylenediaminetetraacetic [EDTA] pH7.4) , which favours the isolation of a single-
cell suspension, and prevents the formation of clumps of glandular tissue. Next, the 
epithelial cell fraction was treated with DNase (Sigma-Aldrich, Madrid, Spain) in the 
same manner as the stromal cell fraction. Finally, both cellular fractions were 
centrifuged at 580 g for 7 min and the pellets were resuspended in DMEM, ready 
for cell counting. 
5.1.2.2 Flow Cytometry  
Flow cytometry (FC) is a powerful and useful technique for the analysis of multiple 
parameters of individual cells in suspension within heterogeneous populations. The 
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flow cytometer performs this analysis by passing thousands of lined up particles 
(usually cells) per second in front of a focused laser beam capturing the light that is 
scattered by each cell as it passes, and producing an individual cell signal. This 
technology enables rapid measurement of certain physical and chemical 
characteristics from a suspension of cells. These signals are collected by the various 
detectors and are subsequently converted into digital signals to allow simultaneous 
measurement of several parameters (size, shape, complexity, phenotype etc.) from 
the same cell. It is essential to use a suspension of single cells or particles, which 
may be live or fixed. 
Fluorescence activated cell sorting (FACS) of live cells separates a population of 
cells into sub-populations based on fluorescent labelling. Sorting involves more 
complex mechanisms in the flow cytometer than a non-sorting analysis. Cells 
stained using fluorophore-conjugated antibodies can be separated from one 
another depending on which fluorophore they have been stained with. 
This technique was used to determine cell viability (see section 5.1.2.3), to isolate 
side population cells (see section 5.1.2.5), and also for the isolation of Lgr5 positive 
cells (see section 5.2.6.4). 
Phases for flow cytometry assay 
 Pre-cytometry step: involves the protocol design, preparation of reagents, 
cell suspensions and their staining with the fluorescent reagents. There are 
different fluorescence markers depending on its type binding to the cell:  
_ Fluorescent markers with covalent binding: fluorochromes which react 
with lipids and proteins. The most common are the phycoerythrin (PE), 
fluorescein (FITC), and rhodamine (ROD). 
_ Non-covalent binding markers: fluorochromes which, due to their 
molecular composition, bind to certain cellular components. Among them 
are RNA and DNA markers (Hoechst 33342, DAPI [diamidino-2-phenylindole 
Dihydrochloride], chromomycin A3, olivomycin, mithramycin, and 
propidium iodide [PI]), membrane potential markers (cyanines and 
rhodamine 123 [ROD]) and markers for membranes and lipids. 
 Flow cytometry step: involves processing the labelled cells and collecting 
data for each of the measurements (parameters). The cell suspension is 
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appropriately processed and stained, injected into the flow cytometer 
chamber, which is designed to pass the cells individually, interacting 
physically with a beam of monochromatic light. The impact of light on the 
cells produces light dispersion in all directions, and at the same time 
fluorescent light is emitted as a result of the excitation laser which the 
sample is subjected to. Two essential parameters describing cellular size 
and components are obtained from flow cytometry analysis: the forward 
scattered light (called forward scatter, FS to 0 degrees) is related to cell 
size, whereas the light scattered at 90 degrees to the light beam (side 
scatter, SS 90 degrees) is related to the internal structure and cytoplasmic 
complexity of the cell. 
 Analysis step: Involves the analysis of the data collected. Photomultiplier 
tubes detect both stray light and fluorescent emissions, and the 
information is then processed and digitized by a computer, generating 
histogram ‘dot-plots’ which are correlated with the desired parameters.  
 
 
Figure 11. Schematic diagram showing a fluorescence-activated cell sorter (FACS). Cells 
are stained with the corresponding fluorochromes and as result are collected as 
independent samples (Image adapted from the Cell Biology website). 
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5.1.2.3 Cellular Viability 
An important aspect related with our research and work with biological samples is 
cellular viability: after subjecting cells to disaggregation and enzymatic digestion 
protocols it is essential to avoid a high rate of cell death. 
To determine the viability of cell suspensions for the epithelium and stroma, we 
used a method based on using propidium iodide (PI, Sigma-Aldrich, Madrid, Spain). 
PI is a fluorochrome which intercalates into double-stranded nucleic acids. The 
membrane of living cells does not allow the passage of PI into the cytoplasm, 
meaning that only cells with damaged or compromised membranes (dead, 
damaged, or apoptotic cells) stain with it. Isolated nuclei can also be stained with 
PI. 
Cell viability was assessed by adding PI to samples at a concentration of 5 μg/mL, 
leaving them in the dark at RT for 15-20 min, and then analysing them with 
cytometric techniques. PI emits a red-orange fluorescence when it is excited with a 
488 nm laser. As a result dead cells can be excluded due to the presence of PI. 
5.1.2.4 Hoechst Staining Protocol 
Viable epithelial and stromal cells from endometrial biopsies, were counted in a 
Neubauer chamber and resuspended in medium (DMEM, 2% FBS [Fetal Bovine 
Serum], and 10 mM HEPES; 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) at 
final concentration of 106 cells per mL. After that, cell staining with the vital dye 
Hoechst 33342 (bisbenzimide H 33342; Sigma-Aldrich, Madrid, Spain) was done. 
Hoechst was added to cell suspensions at a final concentration of 10 μg/mL with an 
incubation period of 90-120 min in darkness in a water bath at 37° C. In addition, 
an aliquot of cells were simultaneously incubated with both Hoechst 33342 and an 
ABC transporter blocker called Verapamil (Vp; Sigma-Aldrich, Madrid, Spain), at a 
concentration of 100 μM. Vp is used as a negative control as it blocks the 
membrane transporters responsible for the exclusion of Hoechst. 
After the incubation period, the cell suspensions were centrifuged at 580 g for 7 
min at 4° C. The resulting pellet was resuspended in HBSS buffer (Hank's Balanced 
Salt Solution [HBSS], 2% fetal bovine serum [FBS], and 10 mM HEPES; Gibco 
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Invitrogen) reaching a concentration of 107 cells per mL, and the suspension was 
kept cold until its analysis on the flow cytometer. Finally, PI was added at a 
concentration of 5 μg/mL so dead cells could be excluded from the analysis. The 
samples were filtered through a 30 μm and 50 μm membrane sieve for cell 
suspensions of stroma and epithelium respectively, to avoid cellular aggregates 
that could hamper the analysis. 
5.1.2.5 Cell Sorting of Side Population Cells 
Hoechst 33342 is a vital dye that has the ability to penetrate into cells through the 
plasma membrane, intercalating with the DNA, particularly in adenine-thymine (AT) 
regions; due to its low cytotoxicity, it is frequently employed as an intercalating 
agent used to visualise the phases of the cell cycle. In 1996 Goodell described the 
enrichment of ABC-type membrane transporters, which are able to efflux Hoechst, 
in undifferentiated hematopoietic cells. When the cells are analysed by flow 
cytometry this efflux results in a specific fluorescence pattern in which cells 
enriched in these transporters are delimited in a low-fluorescence lateral region, 
adjacent to the population of cells in G0/G1 cell cycle phase, termed side population 
or SP cells (Goodell et al., 1996).   
 
Figure 12. Side population cells visualised by FACS. Left panel shows the correlation of 
Hoechst fluorescence with the cell cycle phase. Right panels are images obtained from FACS, 
where the side population cells are obtained by Hoechst efflux (low fluorescence, middle 
panel) and disappear in presence of the Verapamil blocker (right panel). Adapted from 
“Adult stem cells in human endometrium” in Stem cells in Human Reproduction book. 
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To detect the SP, endometrial cells incubated with Hoechst were analysed and 
isolated by FACS (MoFlo® High-Performance Cell Sorter, Dako, Denmark). The 
excitation was performed with a Coherent Enterprise II laser (California, USA) with 
two emission peaks (488 nm and 351 nm) and two excitation peaks, working at 30 
mW. The red and blue fluorescence from Hoechst 33342 were detected through a 
band pass filter of 405/30 nm and 670/20 nm respectively, measuring signals in a 
linear scale. PI fluorescence was detected on a filter with a band pass of 631/20 nm 
on a logarithmic scale. As a result two histograms were produced, one with two-
parameters, displaying blue and red Hoechst fluorescence, and another 
representing the red fluorescence of PI versus FS to exclude dead cells from the 
analysis. 
Finally, PI negative live cells with low Hoechst fluorescence were isolated (as 
putative SP cells), as well as PI negative high Hoechst fluorescence live cells,  which 
were isolated as non-SP (NSP) cells, correlating with the cell population found in S 
phase and the G0/G1 phase transition. 
5.1.2.5 Fluorescence in situ Hybridization (FISH) for the Y chromosome 
Fluorescence in situ hybridization (FISH) is widely used to localise genes and 
specific genomic regions on target chromosomes, both in metaphase and 
interphase cells.  
Briefly, an interphase or metaphase chromosome preparation is produced, placed 
onto a slide, and denatured. Fluorescent probes specific to one region of a 
chromosome and complementary to the known sequence are then hybridized with 
the chromosomes and detected by fluorescence microscopy. There are four types 
of probes that are typically used for in situ hybridization: oligonucleotide probes, 
single stranded DNA probes, double stranded DNA probes, and RNA probes (cRNA 
probes or riboprobes). The probes hybridize to areas on the chromosome which 
have a high degree of sequence similarity. 
In this study, the FISH technique was used to detect the presence of X or Y 
chromosomes. First, the DNA sample (from interphase cells in this case) was 
denatured, separating the complementary strands of the DNA double-helix 
structure. The fluorophore-labelled probe of interest was added to the denatured 
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sample, allowing its association with the DNA in the target site, in a process called 
hybridization, in which a double helix is again formed. As a result, the signal 
emitted by the probe could be observed using a fluorescence microscope. 
 
 
Figure 13. Fluorescence in situ Hybridization (FISH). The technique involves fluorescent 
detection after binding with a small nucleic acid sequence ‘probe’ with a fluorescent 
molecule attached to its corresponding sequence on the target chromosome site (Image 
adapted from online Molecular Methods tools). 
Cell suspensions from SP and NSP fractions cultured for 3 weeks under hypoxic 
conditions (1-2% O2), were trypsinized, treated with 0.075 M potassium chloride, 
and fixed with methanol and acetic acid in 3:1 proportion before proceeding with 
FISH analysis. 
The slides with fixed cells were dehydrated in an ethanol gradient (70%, 85%, and 
100%) for one minute in each bath, and air dried. The mixture of centromeric 
probes for the X chromosome (orange spectrum), Y chromosome (green spectrum), 
and chromosome 18 (aqua spectrum; Poseidon probes, Kreatech, Spain) were 
added to the preparations. Coverslips were carefully added and the slides were 
incubated in a humidified chamber at 73° C for 5 min to denature, and at 37° C ON 
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to hybridize. After that, the slides were washed, firstly with pH 7.5 0.4× SSC-buffer 
(saline sodium citrate buffer)/0.3% NP40 (nonyl phenoxypolyethoxylethanol) in a 
73° C bath for 2 min, and secondly in pH 7.2 2× SSC/0.1% NP40 at RT. Finally, nuclei 
were stained with DAPI Gold (Invitrogen Carlsbad, CA, USA). 
5.1.3 Paraffin-Embedded Endometrial Tissue Analysis 
5.1.3.1 Endometrial Processing 
Endometrial tissue samples were taken from five patients enrolled in the BMT 
study, and from a patient not treated with allogeneic transplant, with fetal 
testicular and human spleen tissues used as controls. 
A small endometrial biopsy fragment was used for histological studies. After 
cleaning the sample of mucus and blood traces, it was placed in 4% PFA (v/v) for 24 
h and then embedded in paraffin according to established protocols. After this 
tissues were dehydrated using ethanol gradient baths of increasing concentration 
(80%, 90%, and 100% [v/v]), and then embedded in xylol. Paraffin-embedded 
samples were sectioned at 3-5μm with a microtome and mounted on glass slides 
treated with poly-Lys (poly-lysine) and incubated overnight at 37° C to facilitate the 
deparaffinization and the adhesion of the tissues to the slide. The final 
deparaffinization was carried out by heating to 60° C for 1 h, followed by 3 
passages with xylol for 10 min, 3 bath solutions of 100% ethanol for 5 min, and a 
subsequent rehydration with alcohols of decreasing concentration (95%, 80%, and 
70%, [v/v] for 5 min each) ending in a water bath, ready to begin the fluorescence 
in situ hybridization (FISH) or immunohistochemistry (see Sections 5.1.3.2 and 
5.1.3.4 respectively). 
5.1.3.2 Fluorescence in situ Hybridization (FISH) for the Y chromosome 
FISH with specific probes for chromosomes X and Y (chromosome enumeration 
probes [CEP], Abbott) was performed (Table II). To test the specific signal for X 
and/or Y chromosomes, endometrial sections from non-transplanted women were 
used for XX signal, whereas fetal testicular tissue was used for XY signal. 
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Probe Location Fluorophores 
CEP X Xp11.1-q11.1Alpha Satellite 
DNA 
Orange/Red Spectrum 
CEP Y Yq12 Satellite III Green Spectrum 
Table II. Probes used for fluorescence in situ hybridization (FISH) for chromosomes X and Y. 
 
Figure 14. Detailed location of CEP X and CEP Y probes in sex chromosomes. The CEP X/Y 
probe is a mixture of a Spectrum Orange-labelled CEP X-DNA-probe and a Spectrum Green-
labelled CEP Y-DNA-probe specific for the alpha satellite centromeric region of chromosome 
X and the satellite III (Yq12) region of chromosome Y (Information provided from Roche 
website). 
After tissue fixation, inter- and intra-molecular cross-links are produced with 
certain structural proteins which mask the tissue antigens. In order to ‘unmask’ 
these antigenic sites antigen retrieval was performed. Thus, a heat-induced antigen 
retrieval protocol with citrate buffer (10 mM Citric Acid, 0.05% Tween 20 
[Polysorbate 20], at pH 6.0) was performed on deparaffinized endometrial sections 
(section 5.1.3.1) in a bath in the microwave using alternating settings 
(maximum/minimum power) to facilitate permeabilization. To increase the 
accessibility to the nucleic acids, an enzymatic digestion was performed in a 0.2 M 
hydrochloric acid (HCl) bath for 10 min, followed by washing for 5 min with distilled 
water and addition of proteinase K (Qiagen, Hilden, Germany) at 10 μg/mL, diluted 
in PBS (Invitrogen Carlsbad, CA, USA) in a bath at 37° C for 10 min. Thereafter, the 
sections were washed with saline sodium citrate buffer (2× SSC) for 5 min and fixed 
with 1% buffered formaldehyde for 10 min, then washed again with SSC-buffer and 
allowed to air dry. 
Following the process described above, dehydration with increasing concentration 
ethanol baths (70%, 80%, and 100%) was performed before applying the solution of 
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centromeric X and Y probes to the slides, and sealing with a coverslip. After this 
they were placed in a humid chamber, and held in in the following temperature 
program: denaturation ramp at 80° C for 5 min and hybridization at 37° C for 72 h. 
In the post-hybridization process, coverslips were carefully removed and the 
sections were washed, firstly with a pH 7.5  0.4× SSC/0.3% NP40 solution in a bath 
at 80° C for 2 min, and a secondly in a pH 7.2 2× SSC/0.1% NP40 solution at RT for 
30 sec. Finally, nuclei were stained with DAPI Gold (Invitrogen Carlsbad, CA, USA) 
and the sections were stored at -20° C until they were visualized with a 
fluorescence microscope. 
5.1.3.3 X/Y Cell Quantification 
The sections were observed on a fluorescence microscope (Leica DM 6000 B/M) 
with a 63× oil immersion objective. The female cells were represented by two 
signals in the orange-red spectrum, corresponding to the X chromosome, while the 
male cells, were visualised with two colours, orange-red and green, represented by 
an X and a Y chromosome respectively. An average of 1000 to 1500 isolated cells 
was counted to analyse the percentage of XY cells present in the endometrium of 
BMT patients. The total number XX and XY cells were quantified using Image-Pro 
Plus Software, Version 6.3 (MediaCybernetics).  
5.1.3.4 Immunofluorescence and Confocal Analysis with CD45, CD9, and Vimentin 
Markers  
After the FISH assay for the X and Y chromosomes was performed, the XY cells 
observed in the endometrium were phenotyped. CD45 antibody was used to 
distinguish hematopoietic cells, and CD9 and Vimentin antibodies were used for 
endometrial epithelial cells and stromal cells respectively. After chromosome 
hybridization, the sections were washed with PBS and were subjected to a blocking 
process with PBS supplemented with 3% bovine serum albumin (BSA), 5% normal 
goat serum (NGS) and 0.05% Tween 20 for one hour at RT to avoid any possible 
non-specific binding. Following this, a permeabilization step with PBS 
supplemented with 0.05% Tween 20 was performed, and the primary antibody was 
added in solution with PBS. 
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The antibodies and dilutions used were: mouse anti-human CD45 diluted at 1:50 
(BD Pharmingen, 555480), mouse anti-human CD9 diluted at 1:20 (Abcam, 49325), 
and mouse anti-human Vimentin diluted at 1:10 (Vm; Abcam, 8069), all incubated 
ON at 4° C.  
After the initial incubation, excess unbound antibody was removed by washing, and 
the samples were incubated with the Alexa 633 F(ab')2 fragment goat anti-mouse 
(Invitrogen, A-21053) fluorescent secondary antibody. This fluorophore was chosen 
because the orange and green fluorophores for CEP centromeric probes for 
chromosomes X and Y respectively had already been used. Alexa 633 has a far red 
emission, which does not overlap with the spectra of the CEP probes. The 
secondary antibody was used at a 1:500 dilution and was incubated for 45 min at 
RT. Finally, to remove any unbound antibody that could result in background noise, 
serial of washes were performed, twice with PBS for 5 min, and twice with distilled 
water for 5 min. Lastly, DAPI Gold (Invitrogen Carlsbad, CA, USA) was added to the 
preparations to stain the cell nuclei and the sections were stored at -20° C until 
they were visualized by confocal fluorescence microscopy.  
To test the signal specificity for each antibody we used human spleen sections as a 
CD45 positive control, and human endometrial tissue (due to its epithelial and 
stromal cell content) as a CD9 and Vm positive control. 
Images were taken with a 63× objective in oil immersion with a Leica TCS SP2 AOBS 
(Leica Microsystems Heidelberg GmbH, Mannheim, Germany) confocal microscope. 
The wavelengths used for excitation of the fluorophores were as follows: 488 nm 
for FITC (green), 561 nm for TRITC (orange/red), 633 nm for Alexa633 (far red), and 
405 nm for DAPI (blue). The two-dimensional images were acquired with a size of 
1024×1024 pixels. Image processing was done with Leica Lite Confocal Software, 
version 2.61. 
5.1.3.5 Telomere Length Analysis by Fluorescence in situ Hybridization 
Telomeres are located at the end of chromosomes and play a key role in protecting 
their integrity. They are composed of tandem repeats of a DNA sequence (TTAGGG 
in vertebrates) and their associated proteins (also called telomere binding proteins) 
which have all been conserved throughout evolution. Telomerase functions to 
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protect the ends of the chromosomes from normal cellular DNA-repair and 
degradation activity, thereby ensuring the correct functionality and viability of the 
cells (Flores et al., 2005). 
The average chromosomal length and percentage of short telomeres in paraffin-
embedded endometrial sections was measured by hybridization with specific 
probes and was observed by fluorescence microscopy. The telomere length is 
measured by telomeric quantitative-FISH (Q-FISH) on interphase nuclei, both on 
tissue sections or cell suspensions, using a technique known as Telomapping (Flores 
et al., 2008). Telomeric Q-FISH is a type of quantitative fluorescence in situ 
hybridization where telomeres are hybridized with a telomeric probe labelled with 
fluorescence (Cy3 PNA-tel). Each telomeric probe recognizes a fixed number of 
telomeric repeats (base pairs). For this reason, the intensity of the fluorescent 
signal from the telomeric probes that hybridize to a given telomere is directly 
proportional to the telomere length. Finally, the fluorescence values are 
transformed into telomere length values for each individual telomere spot within a 
cell, and so the mean telomere length, as well as the percentage of short 
telomeres, in a cell population can be measured. 
Thus, endometrial tissue sections were hybridized with a PNA-tel Cy3 probe and 
signals for Cy3 and DAPI (cell nuclei staining) were acquired simultaneously in 
separate channels using an ultra-spectral Leica TCS-SP2-A-OBS-UV microscope. This 
double labelling creates combined images of each nucleus with the corresponding 
telomeric information. Cy3 fluorescence intensity (telomere fluorescence) was 
measured as the average gray value units (total gray/nuclei area; arbitrary units of 
fluorescence). The average value of fluorescence intensity represents the average 
Cy3 intensity of the total nuclear area and not the average value of individual 
telomere intensities and therefore it is possible discard differences in nuclear size 
which may influence the telomere length measurements. This analysis was 
reported by Life Length, S.L. Madrid, Spain.  
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5.2 Implication of the Lgr5 as a Marker for an Endogenous Endometrial Stem Cell 
Niche  
The use of human origin samples for the development of this study was approved 
by the ethics committee of the Instituto Universitario Instituto Valenciano de la 
Infertilidad (IUIVI). These samples were obtained after explanation of the project 
and signed informed consent by all the patient participants (see Annex II). 
5.2.1 Biological samples and inclusion criteria 
Endometrial biopsies from donors were collected at the Instituto Universitario 
Instituto Valenciano de la Infertilidad (IUIVI). Endometrial samples were taken on 
the day that oocytes were retrieved (day 15 of the menstrual cycle). 
Additional endometrial samples were collected throughout the menstrual cycle to 
investigate Lgr5 expression by western blot (see section 5.2.4). These samples were 
divided into four groups according to the phase of the menstrual cycle: proliferative 
(P; days 1-14), early secretory (ES; days 15-18), mid secretory (MS; days 19-22) and 
late secretory (LS; days 23-28) according to Noyes criteria (Noyes et al., 1975). 
Inclusion criteria for patients were as follows: 
- Age ranged between 18-39 years. 
- Body Mass Index (BMI) of between 19-25 Kg/m2. 
- Absence of endometrial pathologies.  
5.2.2 Detection of the Lgr5 molecule by in situ Hybridization with RNA Probes  
In situ hybridization (ISH) is based on the ability of the nitrogenous bases of nucleic 
acids to establish hydrogen bonds with each other in a specific way. This allows 
specific RNA messengers (mRNAs) to be located at cellular level, by use of 
appropriately labelled RNA sequences (probes). This technique is complementary 
to immunohistochemical studies, allowing molecules to be elucidated at the mRNA 
level. 
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5.2.2.1 Probe Preparation 
RNA extraction 
Total RNA was extracted from endometrial biopsies using the Trizol method 
(Invitrogen Carlsbad, CA, USA). Samples were placed in Trizol and left for 10 min at 
RT, and then 0.2 volumes of chloroform per Trizol-volume used was added.  
The sample was agitated with a vortex and allowed to stand for 5 min at RT, and 
was then centrifuged at 12,000 g for 15 min at 4° C before transferring the aqueous 
phase to another tube. 0.5 volumes of isopropanol were added to this aqueous 
phase per original volume of Trizol used, and it was then incubated for 10 min at RT 
to precipitate the RNA. This was followed by centrifugation at 12,000 g for 10 min 
at 4° C. The supernatant was removed and the precipitate was washed twice with 
70% ethanol (v/v) in water treated with diethylpyrocarbonate (DEPC), and was 
centrifuged a final time for 5 min at 7,600 g at 4° C. The supernatant was discarded 
and the precipitate was dried at RT for 10 min. Finally, it was resuspended in a 
volume of 20 μL of DEPC water. 
After the RNA extraction, its purity was quantified as the absorbance reading at 260 
nm using a NanoDrop (ND-1000 Thermo Fisher, USA) spectrophotometer. The 
criteria established to accept the sample as valid were: 
- Absorbance ratio A260/A280 with a value close to 2. 
- Absorbance ratio A260/A230 with a value between 1.8 and 2.2.  
Variations in these values result from the presence of protein traces, phenol, or 
other contaminants in the RNA that could interfere with the purity of the sample.  
cDNA Synthesis 
Reverse transcription of RNA into complementary DNA (cDNA) was done using the 
reverse transcription system. For this purpose, 1 μg of RNA was used with the 
Advantage Reverse Transcription for PCR kit (Clontech, Palo Alto, CA, USA) 
according to the manufacturer's instructions. 1 μL of oligo dT and DEPC water was 
added to each sample to a final volume of 13.5 μL, and was heated at 70° C for 2 
min to denature the RNA strands and prevent the formation of secondary 
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structures. Thereafter, 6.5 μL of the reaction mixture containing: 4 μL 5× reaction 
buffer, 1 μL dNTPs (10 mM each), 0.5 μL recombinant RNase inhibitor, and 1 μL of 
the MMLV reverse transcriptase (Moloney-Murine Leukaemia Virus) enzyme was 
added to each tube. Samples containing a final volume of 20 μL were incubated in a 
thermocycler (T3000 Thermocycler, Biometra) in a program for 1 h at 42° C 
followed by 5 min at 94° C to stop the reaction and destroy the DNase activity. The 
final product was quantified on a NanoDrop spectrophotometer (ND-1000 Thermo 
Fisher, USA) to check the purity, as described in the previous section, was diluted to 
200 ng/μL, and stored at 4° C until use. 
Polymerase chain reaction (PCR) 
PCR was used to obtain a large number of copies of a particular DNA fragment, 
because DNA polymerases can replicate DNA strands when cycled through 
alternate high and low temperatures, separating newly formed strands of DNA 
after each phase of replication, and allowing new DNA strands to be synthesised 
using the previously formed ones as a template.  
The probe to detect Lgr5 mRNA by FISH was generated by PCR using the primers 
shown in Table III.  These sequences were designed using specialised software 
(Gene Fisher) and the amplified 470 base pair (bp) fragment insert, which was the 
basis for the synthesis of the riboprobe (primer sequences are shown in purple in 
the 5´-3´ direction), was as follows: 
5´GGAGAGTCTGACTTTAACTGGAGCACAGATCTCATCTCTTCCTCAAACCGTCTGCAATCAGTTACC
TAATCTCCAAGTGCTAGATCTGTCTTACAACCTATTAGAAGATTTACCCAGTTTTTCAGTCTGCCAAA
AGCTTCAGAAAATTGACCTAAGACATAATGAAATCTACGAAATTAAAGTTGACACTTTCCAGCAGTT
GCTTAGCCTCCGATCGCTGAATTTGGCTTGGAACAAAATTGCTATTATTCACCCCAATGCATTTTCCA
CTTTGCCATCCCTAATAAAGCTGGACCTATCGTCCAACCTCCTGTCGTCTTTTCCTATAACTGGGTTAC
ATGGTTTAACTCACTTAAAATTAACAGGAAATCATGCCTTACAGAGCTTGATATCATCTGAAAACTTT
CCAGAACTCAAGGTTATAGAAATGCCTTATGCTTACCAGTGCTGTGCATTTGGAGTGTGTGAGA3´ 
Transcript  Primer sequence 5´-3´ Size (bp) 
Lgr5 Forward (Fw) GGAGAGTCTGACTTTAACTGGA 470bp 
 Reverse (Rv) TGCATTTGGAGTGTGTGAGA  
Table III. Primers used for the Lgr5 riboprobe synthesis by PCR in direction 5´-3´. 
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Primers are sequences of oligonucleotides used to hybridize with the desired DNA 
region to be amplified, leading to the initiation of an elongation reaction by DNA 
polymerase. Primers are normally short sequences, ranging between 18 and 22 
nucleotides. The PCR process classically involves a series of 20 to 35 cycles; in each 
cycle there is a change of temperatures which generally consists of the following 
phases: 
Denaturation  
First, the DNA is denatured (the two strands which form it are separated). This step 
can be done in different ways, heating (94-95° C) the sample the most common 
method. The temperature chosen for denaturation depends, among other things, 
on the ratio of GC (guanine-cytosine) that the strand has, as well as its length. 
Other methods, rarely used in the PCR technique, include the addition of salts or 
chemicals. 
Primer hybridization 
Next the primers hybridize i.e., the primer binds to its complementary sequence in 
the DNA template. This requires a temperature drop (generally to 55° C, although it 
may vary, depending on the case, to between 45° C and 65° C). These primers serve 
as the boundaries of the selected region of the DNA molecule to be amplified. 
Extension of the strain 
Finally, the DNA polymerase uses the DNA template to synthesize the 
complementary strand, starting from the primer as the initial support necessary to 
synthesise this new DNA. The temperature is increased to 72° C, the temperature 
at which Taq polymerase is maximally active, geometrically increasing the amount 
of amplified DNA fragments in the reaction with each repetition of the main cycle 
steps. 
The semi-quantitative PCR technique is used to determine the presence or absence 
of specific sequences. Here, PCR was done with 500 ng of cDNA, to which the 
following reaction mixture (final concentration) was added: 1× reaction buffer 
(Bioline, London, England), 3 mM MgCl2 (Bioline), 240 μM dNTPs  (Bioline), forward 
primers (Fw, direction 5´-3´ to 10μM) and reverse primers (Rv, direction 3´-5´ to 
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10μM), 1U Netzyme DNA polymerase  (Bioline). The PCR reaction was performed in 
a T3000 thermocycler (Biometra, Gottingen, Germany). As negative control, the 
cDNA was replaced by bi-distilled water to check for the absence of cellular 
material.  
Each PCR reaction cycle was standardized: initial DNA denaturation was at 95° C for 
5 min, followed by 38 cycles of a) denaturation at 95° C for 1 minute, b) 
hybridization at 54° C for 1 minute, and c) extension at 72° C for 30 sec, followed by 
a final 8 min extension step at 72° C. Samples were subsequently stored at 4° C 
until use. 
The amplified cDNA fragments were separated by electrophoresis for 1 h at 90 V in 
an agarose gel at 1.5% (w/v) and stained with GelRed (Biotium Hayward, CA, USA) 
and finally observed under ultraviolet light. The visualized bands were cut from the 
gel and purified with the Pharmacia elution band kit (Amersham, Barcelona, Spain). 
To verify the correlation of the amplicon with the studied gene, sequencing was 
performed by the Genomic Unit at Valencia University, confirming amplification of 
the correct amplicon. 
Riboprobe synthesis 
The PCR product for the Lgr5 gene was purified with the StrataPrep PCR 
purification kit to remove the primers, unincorporated nucleotides, PCR buffer 
components, and enzyme from the PCR product. The purified product (470 bp) was 
polished with Pfu DNA polymerase to generate blunt-ended DNA. The action of 
DNA ligase allowed this blunt ended DNA to be cloned into the MCS (multiple 
cloning site) of the pPCR-Script Amp SK (+) vector (See Figure 15), according to 
manufacturer's instructions (Agilent Santa Clara, CA, USA). 
The transformation was performed by adding plasmidic DNA to XL10-Gold 
competent cells and incubating for 1 h on ice, and then performing a heat shock for 
45 sec at 42° C. Cells were plated on LB-Ampicillin solid medium, and bacteria that 
had incorporated the plasmid were selected based on their antibiotic resistance. 
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Figure 15. pPCR-Script Amp SK (+) Vector Map. The pPCR-Script Amp SK (+) cloning vector is 
derived from the pBluescript II SK (+) phagemid. This cloning vector includes an ampicillin-
resistance gene, a promoter for expression of the lac gene, T3 and T7 RNA polymerase 
promoters for in vitro production of RNA, an f1 intergenic region for single stranded DNA 
(ssDNA) rescue, the SK multiple cloning site (MCS), which is modified to include the Srf I 
restriction-endonuclease target sequence, and five conveniently located sequencing primer 
sites (Technical datasheet from Agilent manufacturer). 
Colonies with the incorporated insert were visualized as white colonies due to 
disruption of β-galactosidase activity by incorporation of the Lgr5 insert into the 
plasmid vector. White colonies were selected and grown in LB medium at 37° C 
with shaking (150 rpm ON). Bacteria were collected by centrifugation, and plasmid 
DNA was extracted using the EndoFree® Plasmid Purification Kit (Qiagen Hilden, 
Germany). The plasmidic DNA (1 μg/μL) obtained was linearized with restriction 
enzymes: EcoR1 for the sense probe and Sac1 for the antisense probe (New 
England Biolabs, Ipswich, Massachusetts, USA in both cases), in a reaction at 37° C 
ON. Correct DNA sequence cloning and determination of correct orientation was 
confirmed by sequencing using the T3 and T7 primers, and finally assessed with the 
BLAST tool from NCBI.  
The RNA probes were synthesized in vitro by transcription of the coding sequence 
inserted into the plasmid with a DNA-dependent bacteriophage-derived RNA 
polymerase (normally SP6, T7, or T3). The plasmid has two different promoter 
sequences which can initiate synthesis, and these are recognized by different RNA 
polymerases which flank the cloned cDNA. Thus, altering the RNA polymerase can 
result in RNA synthesis complementary to the mRNA expressed in vivo, or in RNA 
identical to the endogenous mRNA. Complimentary RNA is used as a probe; due to 
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its hybridization with the mRNA expressed by the studied tissue, and is called an 
‘antisense’ (opposite direction) probe. The other probe, called a ‘sense’ (same 
direction) probe serves as a negative control because any signal which is detectable 
when using this probe is the result of non-specific binding and not hybridization. 
Sense and antisense probes were generated by in vitro transcription from 1 µg of 
linearized plasmid using the T3 RNA polymerase to create the sense and the T7 
RNA polymerase for the antisense riboprobe. Labelling of the probes was 
performed using nucleotides labelled with dioxygenin (DIG; Roche, Penzberg, 
Germany) in a final volume of 20 μL in a thermo-block at 37° C for 3 h. The labelled 
probes were precipitated using 4 M lithium chloride (LiCl), 250 mM pH 8 EDTA, and 
70% ethanol at -20° C ON. Quantification was performed using a dot-blot assay 
with a pattern of DIG-labelled RNA of known concentration. 
5.2.2.2 De-waxing and Slide Pre-treatment  
Endometrial tissue embedded in paraffin blocks was cut on a microtome to a 
thickness of 5 μm and stretched in a water bath at 37° C. All experiments were 
carried out using ribonuclease-free slides and gloves, and DEPC-treated water in 
order to prevent ribonuclease activity. 
The paraffin-embedded endometrial sections were incubated for 2 h at 60° C and 
were subsequently de-waxed with two xylene baths and rehydrated in a series of 
ethanol solutions of decreasing concentration. Subsequently, they were digested 
with 0.2 M HCl in DEPC water with proteinase K (10 mg/ml) at 37° C for 30 min, and 
washed with 0.1 M triethanolamine and acetic anhydride (0.25% v/v). 
5.2.2.3 Hybridization 
Tissues were pre-hybridized for 3 h at 42° C in a pre-hybridization buffer containing 
60% deionized formamide, 25 mM pH 7.4 Tris-HCl, 1 mM EDTA at pH 8, 0.4 M NaCl, 
dextran sulphate (12% w/v), and Denhardt's solution (1×) with 100 μg/mL of tRNA 
and 200 μg/mL of salmon sperm DNA.  
- Formamide and DTT (dithiothreitol) are organic solvents which reduce the 
thermal stability of the bonds allowing hybridization to be carried out at a lower 
temperature. 
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- Dextran sulphate is added because it becomes strongly hydrated and thus reduces 
the amount of hydrating water for dissolving the nucleotides and therefore 
effectively increases the probe concentration in solution resulting in higher 
hybridization rates.  
- NaCl is a monovalent cation that interacts with the phosphate groups of the 
nucleic acids, decreasing the electrostatic interactions between the two strands. 
- EDTA removes free divalent cations from the hybridization solution, because they 
strongly stabilize duplex DNA.  
- Salmon sperm DNA, tRNA, and Denhardt's solution are added to avoid non-
specific binding of the DIG-labelled probe to the tissue samples. 
Hybridization was performed ON at 42° C with hybridization buffer containing: 
0.1% (v/v) 100 mM DTT (1,4-Dithiothreitol) stock solution, 1% (v/v) sodium 
thiosulfate 10% stock solution and 1% (v/v) dodecylsulfate buffer [SDS] 10% stock 
solution, and the sense and antisense probes at a 200 ng/mL concentration. All 
components used are from Roche, Penzberg, Germany. 
5.2.2.4 Post-Hybridization Treatment 
The following day, tissues were washed with 2× SSC-buffer at RT and afterwards at 
42° C (same temperature as used for hybridization step) with 2× SSC, 1× SSC, and 
0.1× SSC-buffers. After these washes RNase (20 μg/mL) digestion was performed at 
37° C for 1 h with shaking to eliminate any unbound RNA probe. The sections were 
then incubated in a 1× blocking solution (Roche Penzberg, Germany) made with 
Buffer 1 (containing 100 mM maleic acid and 150 mM NaCl at pH7.5) to decrease 
the background noise in non-radioactive hybridization and to detect hybridized 
nucleic acids. 
5.2.2.5 Immunological Detection 
The sections were incubated for two hours at RT with an anti-DIG alkaline 
phosphatase conjugate (dilution 1/500) in a blocking solution with Buffer 1. 
Immunological detection was done by adding a solution formed by Buffer 3 (100 
mM NaCl, 50 mM MgCl2, and 100 mM Tris-HCl at pH 9) containing 1% NBT/BCIP 
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(nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate; v/v) and 
0.1% (v/v) of 1 mM levamisole. The developing process took place at RT for 8 h. 
Counterstaining was performed with 0.1% methyl green. The sections were 
mounted using Kaiser's glycerol gelatine (Sigma, USA) and images were taken at 
63× magnification with a Nikon Eclipse 80i microscope. 
5.2.2.6 Controls 
Human heart muscle was used as a negative Lgr5 ISH control. Lgr5 expression 
present in the crypts of Lieberkühn in the small intestine was used as positive ISH 
control. Sense probes were generated with genetic material identical to the original 
mRNA, meaning it was unable to hybridize, serving as a negative control because 
any signal from this probe was the result of non-specific binding and not 
hybridization. 
5.2.3 Lgr5 Detection at the Protein Level by Immunohistochemistry 
Immunohistochemistry is based on antigen-antibody binding reactions, which 
allows the position of the target molecule to be precisely located in a specific tissue 
at the protein level. 
Endometrial biopsies from different days of the menstrual cycle were collected in 
PBS and fixed in 4% PFA for 24 h to paraffin-embedded, as described in detail in 
section 5.1.3.1. 
Once the endometrial sections were de-waxed and rehydrated antigen retrieval 
was performed by placing the sections in a bath citrate buffer-0.05% Tween 20 pH6 
for 20 min at 95° C to break down the formalin networks and to facilitate antibody 
access. Afterwards the membranes were permeabilized with PBS containing 0.05% 
Tween 20. To avoid unspecific interactions, the slides were passed through two 
blocking solutions: firstly, endogenous peroxidase activity was blocked in the tissue 
itself by using H2O2 for 15 min at RT in darkness. Then slides were then washed and 
unspecific antibody binding was blocked with PBS containing 5% BSA, 5% NGS, and 
0.1% Tween 20 for 1 h at RT. 
The primary antibodies used were rabbit anti-human Lgr5 that recognizes the 
extracellular N-terminal region of the protein, specifically loop 2 (Abgent 
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AP27452d), or the polyclonal rabbit anti-human Lgr5 (Novus 28904). The antibody 
dilution was 1:50 in 3% blocking solution, and samples were incubated ON at 4° C 
to allow binding of the antibody. After several washes with PBS, the secondary 
antibody, biotinylated goat anti-rabbit IgG was applied at a 1:500 dilution in 3% 
blocking solution, and samples were incubated for 30 min at RT. Finally, after 
several washes to remove excess and unbound secondary antibody, staining was 
revealed with DAB (3,3'-diaminobenzidine) according to the manufacturer's 
instructions (Vector DAB Peroxidase Substrate Kit SK-4100). Sections were 
incubated with the ABC complex for 30 min at RT in darkness, washed, and DAB 
developer (comprising 2.5 mL distilled water, 1 drop stock buffer, 2 drops DAB, and 
1 drop of hydrogen peroxide solution) was quickly applied. The reaction was 
stopped at the same time that the positive control took colour. 
After washing with PBS, the slides were counterstained with Harris hematoxylin 
diluted 1/5. Subsequently slides were dehydrated and finally mounted with 
Entellan (Sigma). The sections were visualized using a Nikon Eclipse 80i microscope 
with the 20×, 40×, and 63× objectives. 
The controls used in this case were: 
- Heart muscle as a negative control. 
- Intestine as a positive control for Lgr5 expression in the crypts of Lieberkühn. 
5.2.4 Lgr5 Protein Expression over the Menstrual Cycle assessed by Western Blot  
5.2.4.1 Protein Extraction 
Endometrial biopsies from different days of the menstrual cycle were collected and 
kept at -80° C. To carry out the protein extraction, the samples were washed with 
cold PBS, mechanically disaggregated, and immediately put into lysis buffer for 20 
min on ice to lysate the cells (volumes added were between 20 and 100 µL 
according to the biopsy size). The lysis buffer was composed of 50 mM pH 8.0 Tris-
HCl, 150 mM NaCl, 1% Igepal CA360, 0.5% Na-DOC, 0.1% SDS, and 0.5M EDTA. 
After this the samples were centrifuged at 12,000 rpm for 15 min at 4° C, and the 
supernatant containing the cell protein extract was collected. 
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5.2.4.2 Quantification 
Proteins were quantified using the Bradford method, based on binding of 
Coomassie blue G-250 dye (Bio-Rad, UK) to proteins. In acidic solution the colorant 
exists in two isoforms, one blue and one orange. The proteins in the sample join 
with the blue dye to form a protein-dye complex with an extinction coefficient 
greater than that of the free dye. The absorbance was measured at 280 nm using a 
spectrophotometer, which corresponds to the absorption coefficient wavelength of 
proteins. To determine the total protein concentration present in the sample a 
calibration curve was prepared using a standard protein (BSA). 
5.2.4.3 Western Blotting 
Approximately 40 µg of each protein extract was mixed with Laemmli buffer (Bio-
Rad, UK) with 8% β-mercaptoethanol, and denatured at 95° C for 5 min. The 
technique used was SDS-PAGE (Sodium dodecyl sulphate [SDS] polyacrylamide gel 
electrophoresis [PAGE]), in which proteins are treated with reducing agents, 
causing them to lose their secondary and tertiary structures (for example by 
reducing disulphide bonds [SS] to thiol groups [SH+SH]) and are maintained in this 
denatured state. Thus, the three-dimensional protein structure has no influence on 
electrophoresis, and so the polypeptides are separated based only on size. Protein 
extracts were separated by discontinuous electrophoresis (a 4% polyacrylamide 
stacking gel and a 10% polyacrylamide resolving gel) for 1 h at 180 V.   
Next, proteins were transferred from the polyacrylamide gel to a polyvinylidene 
fluoride membrane (PVDF; Amersham Biosciences, NJ, USA) making the proteins 
accessible for antibody detection. This transfer was accomplished by applying an 
electric field (wet electroblotting), using transfer buffer Tris/Glycine (Bio-Rad, UK). 
The transfer conditions were 160 V for 4 h at 4° C with agitation. 
After the transfer step, the membrane was blocked with 5% skimmed milk powder 
in a PBS detergent with 0.1% Tween 20 in order to saturate all of the possible 
membrane protein-binding sites to prevent nonspecific antibody binding. 
Subsequently, the membranes were incubated at 4° C ON with the primary 
antibodies at a suitable concentration: 1/2000 for mouse monoclonal anti-GAPDH 
(36KDa; Abcam, Cambridge, UK) and 1/500 for monoclonal rabbit anti-Lgr5 
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(100kDa; Novus Biologicals, USA) diluted in 3% milk powder in PBS. The membranes 
were then incubated for 1 h at RT with anti-mouse and anti-rabbit secondary 
antibodies respectively, which were conjugated with horseradish peroxidase (HRP; 
Santa Cruz, CA, USA) at a dilution of 1:2000 in 3% milk powder in PBS. The antigen-
antibody complexes were revealed with the ECL Plus reagent (Amersham 
Biosciences, USA) analysis system and photographed using the Fujifilm LAS-3000 
apparatus. The analysis of bands was performed by densitometry with the Multi 
Gauge Fujifilm program, version 3.0. 
5.2.5 Telomere Length Analysis by Fluorescence in situ Hybridization 
The average length and percentage of short telomeres in endometrial tissue 
sections was analysed as explained in section 5.1.3.5. 
In this case, consecutive sections were used to co-localize the presence of labelled 
cells by in situ hybridization for Lgr5 with hot spot regions obtained by 
telomapping. 
5.2.6 Isolation of Lgr5 Positive Cells 
5.2.6.1 Collection and Processing of Biological Samples  
As explained in section 5.1.2.1 endometrial samples were enzymatically digested 
and subjected to a cell separation process based on a sedimentation gradient to 
obtain epithelial and stromal cells. 
5.2.6.2 Cellular Viability 
Cell viability was assessed by adding PI to the samples at a final concentration of 5 
μg/mL (Sigma-Aldrich, Madrid, Spain) incubating in darkness at RT for 15-20 min, 
and then analysing them by flow cytometry. Propidium iodide fluorescence 
emission is red-orange when is excited with a 488 nm laser meaning that precise 
percentages of live or dead cells could be distinguished based on the presence of PI 
in damaged or dead cells by flow cytometry.   
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5.2.6.3 Endometrial Cell Labelling using Molday ION Rhodamine  
A non-transfection-based method, using fluorescent iron-oxide nanoparticles was 
chosen to label endometrial cells for cell tracking experiments in the in vivo model. 
Molday ION (MION) is a superparamagnetic iron oxide nanoparticle developed as a 
device to label cells by cellular uptake. The label appears to incorporate inside 
endosomes but is not found in the endoplasmic reticulum, Golgi apparatus, 
nucleus, or any other cellular organelles.  Molday ION Rhodamine B (CL-50Q02-6A-
50, [2mg Fe/ml], BioPAL) is a homogeneous, fluorescent iron oxide-based 
superparamagnetic (SPIO) contrast reagent designed to label cells efficiently and 
simply, because it can be visualized by both magnetic resonance imaging (MRI) and 
fluorescence. Rhodamine B is a fluorescent dye with an excitation and emission 
wavelength of 555 and 565-620 nm, respectively. This dual property allowed 
labelled cells to be sorted by flow cytometry and detected by Prussian blue (a 
common histopathology stain) staining due to the iron deposits. 
 
Figure 16. Molday ION Labelling. After incubation, cells incorporate the Molday ION which 
can be detected by Prussian blue staining.  
Epithelial and stromal cells were plated in appropriate conditions with DMEM-F12 
medium containing 10% SBF, 0.1% antibiotics and antimycotics (GIBCO-Invitrogen) 
and incubated at 37° C and 5% CO2. After allowing the cells to adhere ON, Molday 
ION Rhodamine B was added in different concentrations (10 µg/mL, 25 µg/mL, and 
35 µg/mL) to the supplemented medium and incubated for 22 h. The medium was 
aspirated after incubation and cells were washed with PBS (containing calcium and 
magnesium) after which they were visualized using a fluorescent Nikon Eclipse 80i 
microscope.   
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Two further tests were performed at this point:  
(1) A Trypan blue cell viability exclusion test to detect signs of toxicity;  
(2) Quantification of Rhodamine B fluorescence staining by flow cytometry to 
detect any possible cytotoxicity of the compound, and to detect the 
percentage of cellular staining in order to establish an appropriate final 
concentration for future assays. 
 
Thus, one aliquot of the cells was subjected to the Trypan blue test, allowing the 
dead cells to be distinguished from the total cells with a normal light microscope, 
and the other aliquot was centrifuged and resuspended in PBS for flow cytometric 
analysis using a Cytomics FC500 (Beckman-Coulter, CA, USA) flow cytometer. The 
cytometer is equipped with an Argon laser (488 nm, 15 mW) as explained in section 
5.1.2.2. Fluorescence was used at 575 nm in order to detect the Rhodamine B 
signal.  
 
5.2.6.4 Isolation of Lgr5 Positive Cells   
 
Viable epithelial and stromal cell populations were placed in a blocking buffer 
consisting of PBS with 5% BSA for 30 min at RT. After this cells were centrifuged at 
580 g for 7 min at 4° C. A small aliquot of the total cells was taken aside as a control 
and incubated with the secondary but not the primary antibody (referred to as 
isotypes). Incubation with the primary polyclonal rabbit anti-human antibody 
(Novus 28904) against the Lgr5 antigen was performed in PBS with 3% BSA for 1 h 
at 4° C on ice. The antibody was used at a ratio of 1 μL per million cells. After 
incubation the cells were centrifuged at 580 g for 7 min at 4° C and were washed 
with PBS; this washing process was repeated twice to remove any unbound 
antibody. The secondary antibody used was a goat anti-rabbit Alexa 488 at a 
dilution of 1:500 in with 3% BSA for 30 min at 4° C. After this incubation the cells 
were centrifuged at 580 g for 7 min at 4° C and washed with PBS. The cells were 
maintained at 4° C throughout all of the protocols in order to preserve cell viability. 
Finally, the cells were centrifuged at 580 g for 7 min at 4° C and resuspended in 
HBSS buffer. The labelled cells were kept at 4° C ON until processing. 
Before analysing the epithelial and stromal cell suspensions by FACS the cells were 
filtered through 50 μm and 30 μm pore-size filters respectively (Partec, Celltrics) to 
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eliminate possible cell aggregates formed by sedimentation. Finally PI was added at 
a concentration of 5 μg/mL to allow dead cells to be discriminated. 
Cell separation was performed with a high speed FACS Legacy MoFlo (Beckman-
Coulter, USA) equipped with 3 lasers and eight fluorescence detectors. The assay 
protocol also included PI-gating to discard dead cells and thus allow the 
identification and separation of living Lgr5 positive or negative cells. To detect Lgr5-
Alexa 488 and PI, a 488 nm laser was used: fluorescence emission was captured in 
the 525 nm channel for Lgr5-Alexa 488 and in the 620 nm channel for PI. The Lgr5 
positive cell population was separated from the Lgr5 negative population based on 
the analysis of an isotype sample. 
5.2.6.5 Isolation of Lgr5-Rhodamine Positive Cells 
Viable epithelial and stromal cell suspensions labelled with Molday ION Rhodamine 
B were placed in a blocking buffer (PBS with 5% BSA) for 30 min at RT. After this the 
cells were centrifuged at 580 g for 7 min at 4° C, and the protocol described in 
section 5.2.6.4 was followed, with the exception that the FACS settings were 
changed. 
A small aliquot from the entire cell population was separated and used for controls: 
a) unstained cells (before Molday ION labelling), b) Molday ION labelling only, c) 
incubation with only the secondary antibody (isotype) and no Molday ION staining. 
Samples were incubated with the polyclonal rabbit anti-human antibody against 
the Lgr5 antigen (Novus 28904) in PBS containing 3% BSA for 1 h at 4° C on ice. The 
antibody was used at a ratio of 1μL per million of cells. After incubation the cells 
were centrifuged at 580 g for 7 min at 4° C and then washed with PBS twice to 
remove any unbound antibody. The secondary antibody used was a goat anti-rabbit 
Alexa 488 at a dilution of 1:500 in PBS for 30 min at 4° C. After this the cells were 
centrifuged at 580 g for 7 min at 4° C and washed with PBS. The cells were 
maintained at 4° C throughout all of the protocols in order to preserve cell viability. 
Finally, the cells were centrifuged at 580 g for 7 min at 4° C and resuspended in 
HBSS buffer. The labelled cells were kept at 4° C ON until processing. 
Before analysing the epithelial and stromal cell suspensions by FACS the cells were 
filtered through 50 μm and 30 μm pore-size filters respectively (Partec, Celltrics) to 
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eliminate possible cell aggregates formed by sedimentation. Finally, because PI 
interferes with Rhodamine B fluorescence, DAPI (Invitrogen) was added at a 
concentration of 5 μg/mL to allow any dead cells or debris to be discriminated.  
To detect and sort Lgr5-FITC and Rhodamine simultaneously a Moflo Legacy High 
Speed Cell Sorter (Beckman-Coulter, USA) equipped with three lasers (351, 488, 
and 635 nm), two detectors for FS and SS, and eight fluorescence detectors was 
used. The signals for Lgr5-FITC and Rhodamine B were acquired using the 525 nm 
and 620 nm channels respectively, after excitation with the 488 nm laser.  The DAPI 
probe was used to discard the dead cells, which was detected in the 450 nm 
channel, after excitation with the 351 nm laser. Live cells (DAPI negative cells) were 
gated in a FS/DAPI dot plot, and this gate was applied to the Lgr5-FITC/Rhodamine 
B dot plot, where the double positive cells were selected for cell sorting. 
5.2.7 Xenotransplantation Assays with Lgr5-Rhodamine Positive Cells  
Demonstration of the existence of endometrial SSCs which can produce 
endometrial-like tissue in an animal model was essential to provide functional 
evidence of the regenerative capacity of these candidate cell populations in vivo. 
One of the most commonly used animal models in research and regenerative 
medicine is the NOD-SCID (non-obese diabetic/severe combined-
immunodeficiency) mouse. This strain exhibits severe defects in the production and 
function of T cells, is defective in B lymphocytes, and in some cases is also defective 
in NK cell production. This mouse model is immunologically incompetent to treat 
infection or reject transplanted cells or tissues. Therefore it is widely used in the 
scientific community for proof-of-concept experiments to assess the degree to 
which a cell population is undifferentiated (Cervelló et al., 2010; Masuda et al., 
2010; Cervelló et al., 2011; Masuda et al., 2012).  
All procedures involving animals in this study were approved by the Centro de 
Investigación Príncipe Felipe (CIPF) and Instituto Valenciano de Infertilidad (IVI) 
review board ethics committees.  
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5.2.7.1 Experimental Animal Model  
Female NOD-SCID mice (strain code 394; NOD. CB17- Prkdcscid/NCrCrl from Charles 
River Laboratories, Spain) were ovariectomised at 4-5 weeks and then used for 
xenotransplantation experiments. Subsequently, mice were treated with a cocktail 
of analgesic and anti-inflammatory drugs and were anesthetized by sevofluorane 
inhalation, followed by kidney externalization through a dorsal-horizontal incision, 
to enable cell injection. 
In this experimental approach, freshly FACS-sorted Lgr5+Rhodamine+ single cell 
suspensions (2,000-20,000 cells) were resuspended in 30 µl of medium (DMEMF-
12, Sigma-Aldrich, Spain) and injected under the kidney capsule (n=3) on the left 
side. The same number of Lgr5-Rhodamine- cells, in single cell suspension, were 
injected in the left kidney capsule of control mice (n=3).  
 
Figure 17. Experimental Design of the Animal Model Experiments. Four weeks after birth, 
mice were ovariectomised and two weeks later, after recovery, the experiment was started. 
Mice were treated hormonally by administration of estradiol (E2, 0.36 mg/60 days for 11 
weeks) and progesterone (P4, 1 mg/day, for two two-week intervals). After 60 days mice 
were sacrificed and were nephrectomised in order to analyse cell engraftment and 
development in the injected kidneys. 
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During transplantation, estradiol pellets (E2; SE121, 17β-estradiol 0.36 mg/60 days; 
Innovative Research of America) were also implanted subcutaneously in the neck. 
Moreover, mice treated with estradiol pellets were injected subcutaneously every 
day with of progesterone (P4, Dr. Carreras, Hospital 14, Barcelona, Spain) for two 
weeks. After a three-week interval, mice were subjected to a second cycle of daily 
P4 injections for 2 weeks until they were sacrificed. Throughout this assay, 
xenotransplanted mice were maintained in specified pathogen-free (SPF) facility 
and fed ad libitum for 60 days after the initial cell injection. After that, mice were 
nephrectomised according to the experimental protocol. 
60 days after cellular injection, mice were sacrificed by inhalation of carbon dioxide 
(CO2) resulting in immediate death by causing haemoglobin in erythrocytes to 
combine with CO2 thus producing anoxia. Following this, the injected kidneys were 
removed for further analysis, and finally stored in 4% PFA until they were paraffin 
embedded (as described in section 5.1.3.1). 
5.2.7.2 Immunohistochemical Characterization of Candidate Endometrial Tissue  
In order to determine if the Lgr5+Rhodamine+ cell population was able to form 
endometrial-like tissue in vivo, two experimental approaches were taken: Prussian 
blue staining and immunohistochemistry for specific endometrial markers.  
5.2.7.2.1 Detection of Iron Deposits by Prussian Blue Staining  
Prussian blue staining is a histological technique used to visualize the presence of 
iron deposits found inside cells after treatment with Molday ION. It is based on a 
reaction in which ionic iron reacts with acidic ferrocyanide, producing a blue colour.  
The reagent kit used is called ACCUSTAIN® IRON STAIN (Procedure No. HT20, 
Sigma-Aldrich) which provides two solutions 1) the working iron stain solution, 
prepared by mixing equal volumes of potassium ferrocyanide solution (Catalogue 
No. HT20-1) and hydrochloric acid solution (catalogue No. HT20-2) and 2) the 
working pararosaniline solution, prepared by adding 1 mL of pararosaniline 
solution (catalogue No. HT20-3) to 50 mL of water. Both solutions must be freshly 
prepared before use.  
V. Materials and Methods 
77 
 
Paraffin sections from the injected kidneys were deparaffinized for one hour at 60° 
C and rehydrated (5 min in each ethanol bath as described in section 5.1.3.1), and 
placed in distilled water. After this the slides were added to the working iron stain 
solution for 10 min and then rinsed with distilled water. They were subsequently 
stained with pararosaniline solution for 5 min and rinsed with distilled water. 
Finally, the sections were rapidly dehydrated through alcohol and xylene stages 
and mounted with Entellan (Sigma). The sections were visualized with a Nikon 
Eclipse 80i microscope with 20×, 40×, and 63× objectives. 
The controls used to assess the results obtained in this section were:  
- Non-injected kidney, used as negative control. 
- Spleen, used as positive control for iron deposits.  
5.2.7.2.2 Immunohistochemistry for Endometrial Tissue Markers 
With the purpose of characterizing any newly formed tissue present in the kidney 
capsule, immunohistochemistry for Vm and CD9, to search for endometrial-like 
tissue, was performed.  
Sections from the injected kidneys were deparaffinized by heating them at 60° C for 
1 h, followed by 3 passages with xylol for 10 min, 1 bath in 100% ethanol  for 5 min, 
and subsequent rehydration with alcohols of decreasing concentration (95%, 80%, 
and 70%, [v/v] for 5 min in each) ending in a water bath. Antigen retrieval was 
performed in a citrate buffer bath at 95° C in order to break down formalin 
networks and facilitate antibody binding. After this, membrane permeabilization 
with PBS containing 0.05% Tween 20 was performed for Vm staining.  
The slides were then washed and blocked with PBS containing 5% BSA and 0.05% 
Tween 20 for 1 h at RT to reduce unspecific antibody binding. Following this, a 
solution of PBS with 1% BSA and the primary antibody was added. The antibodies 
used were mouse monoclonal anti-human CD9 at a dilution of 1:20 (Abcam, 49325) 
and mouse monoclonal anti-human anti-Vm clone V9, at a dilution of 1:100 (Dako 
M0725) for endometrial epithelial and stromal cells respectively. Cells were 
incubated at 37° C for 1 h in both cases. After buffer washing, the second blocking 
was performed with hydrogen peroxidase by incubation with 3% H2O2
 for 5 min in 
V. Materials and Methods 
78 
 
order to block endogenous peroxidase activity in the tissue. Slides were then 
washed and incubated with biotinylated universal link reagent for 20 min at RT by 
adding enough drops of the link solution to cover the specimen (DAKO Kit, Agilent). 
To stop the reaction, washing-buffer was added.  
Afterwards, slides were placed in solution with streptavidin peroxidase for 20 min 
at RT; to stop the reaction, washing-buffer was added. Finally, slides were 
incubated with the substrate-chromogen solution (DAB Chromogen): one drop of 
DAB chromogen per 1 mL of buffered substrate was incubated on the slides until a 
dark colour developed in the positive control. 
After washing with PBS, the slides were counterstained with Harris hematoxylin 
diluted to 1/5 and subsequently dehydrated (in an increasing concentration 
ethanol gradient as described in section 5.2.3) and finally mounted with Entellan 
(Sigma). The sections were visualized with a Nikon Eclipse 80i microscope with 20×, 
40×, 63×, and 100× objectives.  
The controls used to assess the results obtained in this section were:  
- Non-injected kidney, used as negative control for CD9 and Vm expression. 
- Endometrium, used as positive control for CD9 and Vm expression.  
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VI. RESULTS  
6.1 The Contribution of the Bone Marrow as an Exogenous Source for the 
Endometrial Stem Cell Niche   
6.1.1 Presence of XY Cells of Donor Origin in the Endometrium of BMT Recipients 
The presence of donor-derived cells (Y-chromosome positive cells) in BMT 
recipients´ endometria was examined using the FISH approach. The results 
revealed the presence of XY donor-derived cells in all the endometrial sections 
from BMT-recipients analysed (Figure 18).  
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Figure 18. Detection of XY cells in the endometrium of BMT recipients. (A & B) Human 
endometrial sections from 2 different patients, showing a positive FISH signal corresponding 
to the Y chromosome (green signal) and X chromosome (orange signal) in both epithelial 
and stromal compartments. The presence of donor-derived Y-chromosome cells in the 
endometrium is indicated by white arrows in the figure above. Lower panels containing 
control slides: (A) endometrium as a positive control for the XX chromosome signal and (B) 
fetal testes as a positive control for the XY chromosome signal. Images were acquired using 
a 63× /1.6× oil immersion objective. 
The presence of donor-derived cells in the endometrium is indicated by white 
arrows in the figure above. Although only images from two patients are shown, 
these results were the same for all the BMT-patients included in the study. 
 Control FISH-analyses included an endometrial sample from a healthy non-BMT 
patient; to avoid the possibility of contamination with Y-chromosome positive cells 
via materno-fetal chimerism and male tissues from fetal testes, a non-BMT patient 
who had a previous pregnancy with a boy was selected. As expected, all the cells in 
our controls exhibited orange (X-chromosome positive cells) signals (lower panel 
A), whereas the ratio of the Y-chromosome to X-chromosome positive cells was 
confirmed in male testes (lower panel B). Moreover, the possibility of cell fusion 
was ruled out because of the absence of aneuploidies. 
Table IV. Table summarizing the recipient characteristics and the percentages of XY-
chromosome positive cells obtained in the whole endometrium plus the epithelial and 
stromal fractions from BMT-patients. 
Endometrial tissue sections were analysed by two observers with a total of five 
visual fields per sample scored (around 1000-1500 cells). Donor-derived cells 
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corresponding to Y-chromosome positive cells accounted for 1.7-2.62% of the total 
cell count, with fewer in the epithelial compartment (ranging from 0.45% to 
0.85%), while the percentage of Y-chromosome positive cells in the stromal 
compartment ranged from 1.0% to 1.83% respectively. Interestingly, no correlation 
was found between the time from transplantation to biopsy (from 30 to 210 
months) and the percentage of Y-chromosome positive cells found in the 
endometrium (Table IV). 
6.1.2 Immunophenotype of the XY Donor-Derived Cells in the Endometrium of 
BMT-Recipients  
To assess the phenotype of the XY donor-derived cells in the recipient 
endometrium, we used CD45 to identify cells of a hematopoietic origin, and CD9 
and Vm to locate endometrial epithelial and stromal cells respectively. These 
markers were co-localized in combination with Y-chromosome detection by FISH 
(See Figure 19).  
 
Figure 19. Immunophenotype of the XY donor-derived cells in the endometrium of BMT-
recipients. (A) XY donor-derived cells (marked by arrows: orange and green signals) did not 
co-localize with the hematopoietic marker CD45 (blue signal). Lower panel: spleen as a 
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positive control for CD45. (B) Co-localization of XY donor-derived cells with epithelial marker 
CD9 (blue). Lower panel: endometrial epithelium as a positive control for CD9. (C) Co-
localization of XY donor-derived cells with stromal marker Vm (blue). Lower panel: stromal 
endometrium as a positive control for Vm. Images were acquired using a 63× /1.6× oil 
immersion objective. 
None of the XY donor-derived cells were CD45+ which rules out the possibility that 
these cells were hematopoietic progenitors or of contamination by resident 
leukocytes originating from the BMT (Figure 19A). All the XY donor-derived cells 
present in the glands were CD9+ (Figure 19B) and all the XY donor-derived cells in 
the stroma co-localized with the Vm marker (Figure 19C), suggesting a final tissue-
specific differentiation of XY donor-derived cells. Use of specific tissues for positive 
controls enabled the specific immunoreactivity of the antibodies used to be tested. 
The DAPI signals are shown in grey in all images.  
6.1.3 Analysis of Telomere-Length Regions (Telomapping) in the Endometria of 
BMT-Recipients 
To search for the location of possible endometrial SSC niches within the 
endometrium and whether XY donor-derived cells were part of them, telomere 
length in the endometrial sections from both BMT-recipients and non-transplanted 
patients were examined by telomapping. In all the endometrial sections, ‘hot’ 
regions, associated with long telomeres were located specifically in the stromal 
compartment. Nevertheless differences in terms of telomere-length regions, with 
or without BMT, were not found. Also, some ‘hot’ regions were identified in the 
luminal epithelium of a healthy non-BMT woman.  
Evaluation of telomere length in endometrial sections from all BMT-recipients 
(Patients 1-5) was performed and is represented in Figure 20, together with a 
healthy non-BMT patient control. A colour code in the left part of the image 
symbolizes a colour scale corresponding to different telomeric lengths where the 
longest and shortest telomeres are represented in red and blue respectively. This 
colour code aims to transform the fluorescence intensity values into a map which 
visually shows telomere-length regions within the sample.  
The ‘hot’ regions associated with long telomeres were mainly located in the 
stromal compartment, principally in the patients undergoing BMT: patient 1, 
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patient 2, patient 3, and patient 4. However, in patient 3 some red points were 
close to the luminal epithelial compartment, and in patient 4 these red signals were 
located in the epithelium. In case of the patient 5, only a small sample of 
endometrium was analysed due to her atrophic endometrium. In BMT recipients, 
most XY donor-derived cells were randomly distributed and could not be associated 
with long telomere regions. 
 
Figure 20. Analysis of telomere length in endometrial sections. Assessment of telomere 
length in the endometrial sections from BMT-recipients and a healthy patient. A colour code 
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on the right-hand side of the image symbolizes telomeric length, where the longest and 
shortest telomeres are represented in red and blue respectively. 
6.1.4 Isolation of Endometrial SP Cells and FISH Analyses from BMT-Recipients 
In order to investigate to what extent the donor-derived cells from male donors 
contributed to the endometrial SP (which has been demonstrated to constitute the 
SSC population), this subset of cells from the epithelial and stromal fractions in all 
five BMT recipients was isolated. The table in Figure 21A shows the percentages of 
endometrial SP cells obtained in all 5 patients by cell sorter analysis. 
 
Figure 21. Presence of side population cells in BMT recipients. (A) Table indicating the 
percentages of endometrial SP cells obtained in all 5 patients by cell sorter analysis. 
Percentages are provided for both the epithelial and stromal fractions. (B) Diagram showing 
a typical SP graph and the results of the FISH analyses of epithelial and stromal SP cells, 
revealing the absence of XY donor-derived cells. 
One interesting finding was that there were no epithelial SP cells detected in four 
patients, but that in patient 1 this population was determined to represent 0.04% 
of the total cell population. In patients 1, 2, and 5, the stromal SP percentages 
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ranged from 0.01% to 0.1%, however SP cells were not present in patients 3 and 4 
(Figure 21A). Unexpectedly, the viability of all the samples analysed was very low 
compared that of cells similarly obtained from non-BMT patients (Cervelló et al., 
2010). Figure 21B shows a typical SP graph; FISH analyses were later performed on 
these isolated SP cells. Results for epithelial and stromal SPs from BMT-patients 
revealed the absence of XY donor-derived cells. It is noteworthy that one XY cell 
was observed in a total of 100 FISH-analysed cells in the control NSP stromal 
fraction sample from patient 4.  
 
6.2 Investigation of the Lgr5 Marker to Identify the Endogenous Endometrial 
Stem Cell Niche 
Stem cell niches are usually identified based on the expression of specific protein 
markers on the SSCs that can be tracked and localized. The Lgr5 gene is a multi-
pass-membrane protein, with 3 domains: a large extracellular domain with multiple 
leucine-rich repeats that mediate ligand interaction, a transmembrane domain, and 
an intracellular domain for signal transduction. 
6.2.1 Detection of Lgr5 RNA by in situ Hybridization  
The in situ hybridization technique allows specific gene expression to be localized 
within the cellular environment. To generate the probes the vector pPCR-Script 
Amp SK (+) was used to clone the Lgr5 sequence into the MCS. After labelling with 
DIG the riboprobes were precipitated. Two specific riboprobes were generated for 
Lgr5 mRNA: T7 as the antisense and T3 as the sense riboprobe. 
The controls used in the assay allowed the binding specificity to be determined 
during the hybridization. Therefore, human small intestine was chosen as positive 
control because of reports of Lgr5 expression in the literature (Baker et al., 2007), 
whereas human heart tissue was selected as negative control, because Lgr5 
expression is not reported in this tissue in the Atlas Protein Database.  
Therefore the antisense (T7) and sense (T3) riboprobes were used with these 
tissues to allow the hybridization-produced signal to be distinguished from the 
background (See Figure 22). 
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Figure 22. Controls used for the Lgr5 in situ hybridization. Small intestine was used as a 
positive control for Lgr5 expression; signals are indicated with white arrows, whereas heart 
tissue was the negative control. Two different riboprobes were generated: T7 antisense with 
a sequence complementary to Lgr5 allowing binding, and T3 sense with the same sequence 
which was unable to bind (negative control of the technique itself). Images were taken at 
40× magnification. 
In situ hybridization results revealed the existence of Lgr5 positive cells in human 
endometrium at the mRNA level; the antisense probe hybridized with the 
endometrial tissue but fewer cells were stained positive in the epithelial and 
stromal area. Interestingly these cells were located mainly in the perivascular 
regions as shown in Figure 23. The NBT/BCIP colorimetric reaction causes a brown 
signal to precipitate, indicating specific binding of the mRNA Lgr5-DIG probe, 
whereas nuclei showed up in green only.  
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Figure 23. Detection of Lgr5 mRNA expression in endometrium by in situ hybridization. 
Positive signals from the T7 antisense riboprobe are shown with black arrows, whereas no 
signal was detected with the T3 sense riboprobe. Images were taken at 63× magnification. 
 
6.2.2 Expression of Lgr5 in the Human Endometrium 
Lgr5 expression was evaluated in the human endometrium throughout the 
menstrual cycle, in both the proliferative and secretory phase. The 
immunoreactivity was shown by DAB as a characteristic brown signal, whereas 
nuclei were stained with hematoxylin. After determining that the 
immunohistochemical controls (human small intestine as a positive control and 
human heart as a negative control), were functioning correctly, several endometrial 
samples were studied.  
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Figure 24. Controls used in immunohistochemistry for Lgr5. Small intestine was used as a 
positive control for Lgr5 expression (signals are shown with black arrows), whereas heart 
tissue was the negative control. Images were taken with a microscope at 40× magnification. 
 
Cells marked as positive for the Lgr5 antibody (indicated with black arrows in the 
pictures) were localized in the epithelial glands and perivascular regions of the 
stromal compartment, with no apparent differences in the frequency or intensity of 
the signal throughout the menstrual cycle (Figure 25). Therefore, 
immunohistochemical analysis revealed specific signals (cytoplasmic and 
membrane positions, according of the antibody used) located in the lower 
functionalis, near the basalis layer, which were most frequently found in stromal 
cells. 
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Figure 25. Lgr5 signal localization in proliferative and secretory endometrium by 
immunohistochemistry. Positive signals are indicated with black arrows and are found in 
the stromal area, epithelial glands, and surrounding blood vessels. Images were taken at 
40× magnification. 
Furthermore, the expression of the Lgr5 protein was also confirmed by western 
blot analysis. Samples collected in all stages of the menstrual cycle: proliferative 
(P), early secretory (ES), mid-secretory (MS), and late secretory (LS) were included, 
as shown in Figure 26, where GAPDH expression was also included in order to 
normalize the expression of the Lgr5 molecule. Increased expression was 
discernible in the P phase versus the other phases, although the results were not 
statistically significant (n=2).  
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Figure 26. Expression and quantification of the Lgr5 protein in the endometrium 
throughout the menstrual cycle by western blot.  Left image shows the expression of Lgr5 
and GAPDH throughout the menstrual cycle (P: proliferative; ES: early secretory; MS: mid-
secretory; LS: late secretory); the right image shows quantification of the Lgr5 protein 
throughout the menstrual cycle, normalized to GAPDH protein expression. 
6.2.3 Correlation of Lgr5 Positive Cells with Telomere Length 
The telomerase enzyme, which prevents telomere shortening at each cell division, 
maintains telomere length, and it is expressed in stem cells including germ cells, 
embryonic stem cells, and in the niche of several adult tissues. The technique 
known as telomapping as mentioned above, is a type of quantitative confocal 
fluorescence in situ hybridization which displays the gradient of telomere lengths 
that exists in a given adult tissue; the longest-telomere cells are mapped in red and 
the shortest are shown in blue (Flores et al., 2008).  
SSCs from skin, small intestine, testis, cornea, and brain have all been investigated 
in the mouse model in this way (Flores et al., 2008). Specific ‘hot’ regions (red), 
which corresponds to cells with the longest telomeres, were identified in the 
human endometrium using this technique. Interestingly, a few of the Lgr5 mRNA 
signals obtained by in situ hybridization (Figure 27A) co-localized with some of the 
cells with the longest telomeres (Figure 27B), suggesting that Lgr5 cells are 
associated, at least in part, with a long telomere phenotype. Consecutive 
endometrial sections were used for in situ hybridization and telomapping analyses, 
thus enabling any possible correlation to be identified. 
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Figure 17. Consecutive endometrial sections co-localizing Lgr5 mRNA signals and 
telomapping. An Lgr5 positive cell is indicated with a white arrow (left panel) and the same 
cell is indicated in the right panel which contains telomere-length measurement data; note 
the amplified area. The box in the right panel indicates the colour scale which corresponds 
to telomere length. 
6.2.4 Endometrial Cell Labelling using Molday ION Rhodamine  
Molday ION Rhodamine B, a superparamagnetic iron oxide (SPIO) nanoparticle with 
a fluorophore incorporated into its structure (to allow for staining and cell tracking) 
was used to label cells by cellular uptake.  
Both types of endometrial cell (stroma and epithelium) take Molday ION 
Rhodamine B up, as shown by the fluorescence of these cells after the incubation 
period, as illustrated in Figures 28A and 28A. It was essential to check cellular 
viability with a Trypan blue exclusion test for the three different Molday ION 
Rhodamine B concentrations used (10µg/mL, 25µg/mL, and 35µg/mL) to test for 
cytotoxicity. Neither stromal nor epithelial SPIO-labelled cells exhibited signs of 
cytotoxicity; in the case of stromal cells, even at the highest concentration of 
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35µg/mL, the viability was around 91% (Figure 28B) while in epithelial cells it was 
around 88% in the same conditions (Figure 29B). 
Rhodamine B fluorescence staining was quantified by flow cytometry; cell 
suspensions were analysed using a Cytomics FC500 cytometer (Beckman-Coulter, 
CA, USA), to detect the Rhodamine fluorescence signal at 575 nm. Stromal cell 
staining was high (between 82-93%), independent of the SPIO concentration used 
(Figure 28C). Taken together with the viability assay data, Molday ION Rhodamine 
B was used at 10µg/mL with stromal cells all the following experiments.  
 
 
Figure 28. Staining of stromal cells with SPIOs. A) Rhodamine B fluorescence in stromal 
cells due to incubation with SPIO. B) Percentages of cell viability are shown for the different 
SPIO concentrations used. C) Corresponding percentages of Rhodamine B fluorescence are 
shown for the different SPIO concentrations used. 
 
However, the results for Rhodamine B staining in epithelial cells were not 
acceptable: even at the top concentration used (35 µg/mL) the percentage of 
staining achieved was around 40% (Figure 29C). For this reason the concentration 
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of Molday ION Rhodamine B used to stain epithelial cells was increased to 50µg/mL 
(data not shown). 
 
Figure 29. Staining of epithelial cells with SPIOs. A) Rhodamine B fluorescence in stromal 
cells due to incubation with SPIOs. B) Percentages of cell viability are shown for the different 
SPIO concentrations used. C) Corresponding percentages of Rhodamine B fluorescence are 
shown for the different SPIO concentrations used.  
6.2.5 Isolation of Lgr5-Rhodamine Positive Cells in Endometrium  
Isolation of Lgr5 positive cells in the endometrium 
After mechanical disaggregation and enzymatic digestion of the endometrial tissue, 
a suspension of viable single cells was obtained. Epithelial and stromal cells were 
labelled with an unconjugated rabbit anti-human Lgr5 antibody (Novus 28904), 
followed with a goat anti-rabbit Alexa 488 secondary antibody. The whole process 
was carried out on ice to preserve cell viability. 
To minimize the background signal some samples were also incubated with isotype 
controls in order to establish the appropriate baseline settings on the Legacy MoFlo 
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high speed fluorescence activated cell sorter (Beckman-Coulter, USA) used for the 
experiments. 
Following this, a total of 16 samples (n=16) each of epithelial and stromal cells were 
examined. A mean of 1.68% Lgr5 positive staining was observed for epithelial cells, 
with an average viability value of 56.38%. In the case of stromal cells, a mean of 
0.83% Lgr5 positive staining was observed, with an average viability value of 
60.20%. Data from a single exemplary analysis is shown in Figure 30. 
 
Figure 30. Flow cytometry diagram showing Lgr5 staining for epithelial and stromal cells. 
Panel A shows the staining for epithelial cells whereas Panel B shows stromal cell staining. 
Isolation of Lgr5-Rhodamine B Positive Cells in the Endometrium 
Using the conditions determined in previous experiments for Molday ION 
Rhodamine B and Lgr5 staining in epithelial and stromal endometrial cells, double-
fluorescence positive Rhodamine B (Molday ION Rhodamine B) and FITC (Lgr5-
Alexa 488) cells were sorted. Unstained cells, as well as cells incubated with only 
the secondary Alexa 488 antibody, were used to create sorting gates in order to 
optimize the detection and isolation of the desired cells using a MoFlo Legacy high 
speed cell sorter (Beckman-Coulter, USA).  
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Figure 31 shows FITC-Alexa 488 fluorescence in the FL1 channel (x-axis) and  the 
Rhodamine B signal in the FL3 channel (y-axis), with DAPI staining to exclude dead 
cells and debris in the FL6 channel (not shown). Note that that R6 region represents 
the desired sorting population of double-fluorescence positive Lgr5-Alexa 488 and 
Rhodamine B cells. 
 
Figure 31. Flow cytometry diagram showing the double staining for Lgr5 and Rhodamine 
B in both epithelial and stromal cells. Panel A shows the double staining for Lgr5-Alexa 488 
and Rhodamine B in epithelial cells; Panel B shows controls: unlabelled cells (upper panel) 
and cells incubated only with Alexa 488 (lower panel). Panel C shows Lgr5-Alexa 488 and 
Rhodamine B double staining in stromal cells; Panel D shows controls: unlabelled cells 
(upper panel) and cells incubated only with Alexa 488 (lower panel). 
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6.2.6 Xenotransplantation Assays with Lgr5-Rhodamine Positive Cells  
Once the Lgr5+Rhodamine+ cells were sorted the xenotransplantation assays were 
performed. Freshly isolated Lgr5+Rhodamine+ and Lgr5-Rhodamine+ single cell 
suspensions (2,000 to 20,000 cells in each case) were injected under the kidney 
capsule on the left side of NOD-SCID mice (n=3 in each case), as summarized in 
Table V.        
Lgr5+Rhodamine+ cells (n=3) Lgr5-Rhodamine+ cells (n=3) 
2,000 Lgr5+Rhodamine+ cells (C) 2,000 Lgr5-Rhodamine+ cells (B) 
4,700 Lgr5+Rhodamine+ cells (F) 4,700 Lgr5-Rhodamine+ cells (E) 
20,000 Lgr5+Rhodamine+ cells (D) 20,000 Lgr5-Rhodamine+ cells (A) 
Table V. Table summarizing the injections with one of the two types of sorted cells, 
(Lgr5
+
Rhodamine
+
 and Lgr5
-
Rhodamine
+
) cells that each mouse received.  
Unfortunately, mice A, E, F died during the three month experimental period. Only 
results from the remaining mice are shown (see Figure 32).  
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Figure 32. Staining for Prussian blue (Rhodamine B
+
), and endometrial cell markers CD9 
and Vm in the cell-injected kidneys. Sections from the left kidneys of all three mice are 
displayed, and show Prussian blue, CD9, and Vm positive signals. Positive controls are shown 
in the last column: spleen and endometrium for Prussian blue and CD9/Vm staining 
respectively. Images were taken at 40× and 100× magnification. 
All three kidneys showed de novo tissue formation within the kidney capsule. In 
Figure 32 a dashed line delineates the kidney tissue from the newly formed tissue 
above the line and an arrow shows the new tissue growth which was greater when 
a larger number of cells were injected. Only this area shows positive staining for 
Prussian blue, which shows up as blue spots, indicating that the injected cells were 
Rhodamine B positive independent of Lgr5 positivity. Spleen was used as a positive 
control. This data suggests that all newly-formed tissue originated from the 
injected cells.    
Immunohistochemistry for CD9 and Vm was performed in order to test if the de 
novo formed tissue present in the experimental mouse kidney capsules was 
endometrial-like: i.e. if it contained specific human epithelial and/or stromal cells. 
Endometrial tissue was used as a control for CD9 epithelial and Vm stromal cell 
staining. The experimental tissue staining pattern revealed some positive signals 
for CD9 and Vm, which corresponded to the Prussian blue stained regions, 
highlighted with black arrows in all cases in Figure 32. Thus, these results suggest 
that at least some endometrial-like tissue was formed de novo from the cells 
injected in these experiments. 
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VII. DISCUSSION  
SSCs are the main players in the tissue homeostasis process, supporting ongoing 
tissue regeneration by replacing the cells lost during natural cell cycling or injury. 
They reside in a special microenvironment termed the ‘niche’ which varies in its 
nature and location depending on the tissue the cells reside in. It is hypothesized 
that abnormal functioning of endometrial SSCs and/or their neighbouring niche 
cells may contribute in the onset of gynaecological pathologies associated with the 
endometrium such as endometriosis, adenomyosis, endometrial cancer, or 
Asherman´s syndrome. Ultimately, better understanding the function of these 
putative SSCs will help to treat these endometrial disorders. However, the first key 
step in this process is the identification, location, and characterization of this 
subset of cells.  
 
Many groups in the endometrial SSC field have focused their efforts on discovering 
markers and techniques to isolate this tissue-specific stem cell population. Thus in 
the last 5 years accumulated evidence has confirmed the existence of SP cells in 
human endometrium, and indeed has also demonstrated that the SP technique 
could represent a useful tool to isolate human endometrial SSCs (Kato et al., 2007; 
Tsuji et al., 2008; Cervelló et al., 2010; Masuda et al., 2010; Cervelló et al., 2011; 
Cervelló et al., 2012). Human endometrial SP cells have high clonogenic efficiency, 
express typical and well-described undifferentiated genes, and present a MSC 
phenotype (CD90, CD105, and CD73 positive, and CD34 and CD45 negative). They 
also have the ability to differentiate in vitro into mesenchymal lineages such as 
adipocytes, osteocytes, and chondrocytes. The final proof of the existence of 
human endometrial SSCs would therefore be demonstrated by the reconstruction 
of human endometrium in an animal model (Cervelló et al., 2010; Masuda et al., 
2010; Cervelló et al., 2011).  
 
Future studies are likely to identify endometrial SSC-specific markers, allowing their 
identification and isolation from this tissue. Candidate tissue-specific stem cell 
surface markers such as PDGF-Rβ, CD146, and W5C5 (Gargett et al., 2009; Spitzer 
et al., 2012; Masuda et al., 2012) were reported in the human stromal cell 
compartment, but definitive endometrial SSC markers have so far remained 
elusive. 
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Our study: The Contribution of the Bone Marrow as an Exogenous Source for the 
Endometrial Stem Cell Niche   
 
The data presented in this study can be used to extend previous reports on the 
contribution of bone marrow to endometrial regeneration. We herein confirm that, 
in a pathological model of females who received BMT from HLA-identical male 
donors to treat hematologic cancers, some XY cells originating from the donor BM 
migrate to the recipient endometrium and transdifferentiate, contributing to 1.7% 
to 2.62% of the stromal and the total epithelial cell compartment.  0.45% to 0.85% 
of the XY donor-derived cells in the epithelial compartment displayed specific 
epithelial markers like CD9, and 1.0% to 1.83% of the XY donor-derived cells in the 
stromal compartment expressed Vm. This scenario supports the capacity of BM 
donor-derived cells to give rise to human endometrial tissue. Moreover functional 
endometrium in these patients was demonstrated by its ability to support ongoing 
pregnancy, such as in patients 1 and 3.    
Different studies have demonstrated that multipotent human BM-donor derived 
cells differentiate into cell types of the functionally competent endometrium. In 
2004, Taylor identified donor cells in the endometrium of recipients after BMT for 
the first time, and confirmed their typical epithelial and stromal features, and their 
corresponding hematopoietic CD45 negative phenotype (Taylor et al., 2004). In line 
with this, Ikoma assessed firstly, the phenotype of these unexpectedly plastic BM 
cells, showing a typical expression pattern of the epithelial (Cytokeratin, Estrogen 
Receptor-α) and stromal (CD10) compartments in the absence of CD45 marker, and 
secondly by demonstrating successful pregnancies in two of the three patients 
analysed (Ikoma et al., 2009). The presence of donor-derived endothelial cells in 
the endometrium has also been described to contribute to the formation of new 
blood vessels in this tissue during ongoing pregnancy, although only one case has 
been reported (Mints et al., 2008).  Moreover patients from previous reports with 
donor-derived cells in their endometrium had undergone a whole unfractioned 
bone marrow transplant, which contains a heterogeneous population of cells, 
including a population of primitive HSCs and MSCs which could have also 
contributed to the endometrium. Conversely, a very recent report in which patients 
received peripheral blood stem transplantation consisting in an enriched 
population of HSCs obtained by G-CSF mobilization confirmed that recipients do 
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not exhibit cell engraftment in the endometrium, suggesting that HSCs do not 
contribute to the endometrial SC pool (Wolff et al., 2013). There is very little known 
about the cellular subpopulations from the BM which can contribute to uterine 
function. 
Similarly, endometrial engraftment has been demonstrated in two murine models; 
Du and Taylor demonstrated BM stem cell-derived de novo development of the 
endometrium after injury, suggesting a link between endometriosis and immune 
disorders (Du and Taylor, 2007). Following BMT, Bratincsak and Cols detected 
murine donor-derived cells in the epithelial and stromal endometria of recipient 
animals, where CD45+ cells played an important role in the stromal compartment, 
and were found to be a putative source of cells for epithelial regeneration 
(Bratincsak et al., 2007). The role of G-CSF in uterine repair was also investigated in 
murine endometria, where reduced BM-cell migration was observed (Du et al., 
2012); here G-CSF seems to be less effective than it is in ischemia reperfusion and 
cerebral ischemia therapies (Lu and Xiao 2007; Ieishi et al., 2007). Taken together, 
these results suggest that perhaps MSCs derived from BM are responsible for 
uterine repair, possibly due to their similarities with stromal endometrial cells (Du 
et al., 2012). 
This study contributes new evidence, demonstrating that XY donor-derived cells 
can be considered as a limited exogenous source of transdifferentiated 
endometrial cells rather than a cycling source of BM-derived stem cells. Firstly, 
these cells did not incorporate into the endometrial SP, which is broadly considered 
to be the endometrial SSC population because two independent groups have 
demonstrated ability of these SP cells to regenerate the human endometrium after 
their injection into the subcutaneous tissue (Cervelló et al., 2010) or the renal 
capsule (Masuda et al., 2010; Cervelló et al., 2011; Masuda et al., 2012) of NOD-
SCID mice. Nonetheless, it is possible that BM-derived cells induce or favour the 
endometrial SP population compartment as an exogenous niche in response to a 
physiological demand. Secondly, XY donor-derived cells were not associated with 
the putative SC niches, as assessed by telomapping long-telomere regions (Flores et 
al., 2005; Flores et al., 2008). This approach enables cells with different telomeric 
lengths to be analysed, and was recently used to identify SSCs in adult tissues and 
organs like skin (Flores et al., 2005) and human colon (Jung et al., 2007).   
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Finally, engraftment percentages were very low and no correlation was found 
between the time from transplant and the engraftment efficiency, suggesting that 
the cells terminally differentiated randomly, perhaps due to hormonal regulation, 
as demonstrated by the absence of CD45 expression. In physiological terms, the 
transient infiltration of BM derived cells occurs in each menstrual cycle (Meng et 
al., 2007; Taylor et al., 2004). Likewise our results indicate that a final 
differentiation from the BM cell population to endometrial tissue might occur; this 
event is not related with the capabilities of endogenous endometrial stem cells 
because we demonstrated that no endometrial SP cells originated from the BM. 
Therefore, we suggest that BM cells do not contribute to the endometrial SSC pool 
in situ, but might contribute to form differentiated endometrial cells, although to a 
limited extent, in pathological conditions.  
Similarly, XY donor-derived cells were not detected in the recipients’ endometrial 
SP fraction. It is unlikely that the Y-chromosome is lost during engraftment as 
reported in lung tissue of a murine transplantation model (Herzog et al., 2007), 
because endometrial cells do not form heterokaryons, and cell fusion was ruled out 
by chromosomal analyses.  Hypothetically, dormant BM stem cells could become 
activated after stress or injury and therefore result in their mobilization from BM 
(Zapata 2009). Therefore our data raise questions about the mechanisms that 
control the differentiation of BM cells into different endometrial cell types, and 
why BM contribution is more important in the stromal compartment than the 
epithelial cell compartment. One hypothesis is that BM stem cells could provide 
factors that favour the reactivation of endogenous SSCs in the damaged 
endometrial niche.   
It is surprising that in our study we discovered a reduced SP size compared to non-
transplanted patients, which may be due to the use of chemotherapeutic agents. 
Nevertheless, the largest retrospective study, which consists of 229 centres in the 
European group for blood and marrow transplantation (EBMT), and includes 
patients who conceived naturally or by assisted reproductive techniques (ART) 
after BMT, demonstrates that the recipients’ endometria were functional and 
concludes that the outcome of a pregnancy after BMT is likely to be successful 
(Salooja et al., 2001). The latest publication on this topic assessed endometrial 
renewal in an Asherman’s syndrome patient throughout the intrauterine 
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administration of BMSCs. The clinical evidence derived from this study confirms 
that the stimulation of dormant endometrial SSCs into a cell proliferation status to 
help regenerate damaged endometrium by BMSCs is a feasible hypothesis (Gargett 
and Healy, 2011). Therefore, BMSCs might reactivate a dormant or injured 
endometrial SSC niche, serving in the re-activation of a natural endogenous 
process. 
Our study: Investigation of the Lgr5 Marker to Identify the Endogenous 
Endometrial Stem Cell Niche 
In 2007, Clevers’ laboratory performed breakthrough research focused on the 
identification of the genes responsible for self-renewal in small intestinal mucosa. 
From 80 genes identified as regulated by Wnt signalling, expression was restricted 
to the intestinal crypt bottoms in only 11 of them (Van der Flier et al., 2007). 
Notably one of these genes was expressed in the crypt in a distinctive manner, this 
gene, termed leucine-rich repeat-containing heterotrimeric guanine nucleotide-
binding protein coupled receptor 5 (Lgr5), is a cell surface receptor that specifically 
associates with the Frizzled and LPR protein receptors, which are activated by 
extracellular Wnt molecules to trigger canonical Wnt signalling, thus increasing 
gene expression.  
Lgr5 knockout mice are non-viable, their death being caused by gastrointestinal 
tract dilation and malformations affecting the tongue and lower jaw that result in 
serious respiratory problems (Morita et al., 2004). Clevers’ group generated 
heterozygous Lgr5-lacZ mice to serve as an in vivo model to identify the exclusive 
expression of Lgr5 (which specifically marks the cycling base columnar cells of the 
crypt [CBCs]) by lineage tracing experiments. The cycling nature of the Lgr5 stem 
cell population is contradictory to the quiescent cell population located at position 
+4 of the crypt, which until then had been considered the only stem cell population 
in the small intestine (Barker et al., 2007). The coexistence of both populations is 
regulated by a specific microenvironment in which opposing signalling pathways 
are either in on or off status, controlled respectively by Wnt and BMP (Li and 
Clevers, 2010). In situ hybridization studies in mice revealed a limited number of 
Lgr5 cells located at the crypt bottom with an actively cycling nature. This exclusive 
expression pattern was clearly different from genes marking Paneth or TA cells 
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(Barker et al., 2007). Lgr5 cells from mouse intestinal crypts also showed significant 
telomerase activity: a key characteristic of stem cells, as previously explained 
(Schepers et al., 2011).  
Small intestine mucosa Lgr5-positive cells are actively cycling, retain BrdU labelling, 
and express Ki67 and phospho-histone H3 (Barker et al., 2007). In fact, there are 
significantly increased numbers of Lgr5 cells found in colon and rectum cancers, 
and this expression is even higher in metastatic tumours compared with primary 
tumours, suggesting that Lgr5 overexpression is associated with abnormal cellular 
proliferation and metastasis (Becker et al., 2008; Uchida et al., 2010; Takahashi et 
al., 2011). Characteristic features, related to endoderm origin, suggest that Lgr5 
could also be considered a mucosal stem cell marker in organs such the small 
intestine, colon, and stomach. Lgr5 expression in all these tissues was confined to 
CBCs in the intestinal crypt, the colon crypt base, and the base of pyloric glands in 
the stomach respectively (Barker et al., 2007; Barker et al., 2010).  
Lgr5 also acts as a hair follicle (i.e. ectodermal origin) stem cell niche marker. Gene 
expression profile studies documented that Lgr5 expression was enriched in bulge 
cells, and lineage tracing experiments distinguished it in the hair germ during late 
telogen/early anagen phases, as well as in the hair matrix during the late anagen 
phase (Morris et al., 2004). The Lgr5 positive population isolated from the bulge 
constituted around 0.6% of the parent cell population, and in vitro these cells 
formed large colonies with a high clonogenic efficiency when compared to Lgr5 
negative cells taken from the same population. To test follicle reconstitution, Lgr5 
positive cells sorted by FACS were transplanted into nude mice and were able to 
completely regenerate hair follicles at the transplantation sites (Jaks et al., 2008). 
Lgr5 cells have also been traced in the kidney in Lgr5-enhanced green fluorescent 
protein (EGFP)-ires-CreERT2 experimental model reporter mice, where they remain 
restricted to cell subsets within developing nephrons. These cells give rise to the 
ascending limb of Henle’s loop and the distal convoluted tubule in mature 
nephrons, although this expression was permanently silenced at postnatal day 7. 
These data suggest that Lgr5 cells are likely stem or progenitor cells involved in 
kidney formation, but their absence in the mature organ might lead to slow cell 
turnover (Barker et al., 2012).  
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These findings suggest that Lgr5 is a SCC marker in tissues derived from endoderm, 
ectoderm, and also probably mesoderm, making it a potentially universal SSC 
marker.  
The Wnt signalling pathway plays an important role in the maintenance and 
activation of the stem cell reservoir (Ivanova et al., 2002; Logan et al., 2004; 
Haegebarth and Clevers, 2009). Wnt family members are required during 
embryological development of the female reproductive tract, with Wnt4 and Wnt-
7a identified as key regulators of female Müllerian duct development (Stark et al., 
1994; Vainio et al., 1999). Wnt9b, which is important in the outgrowth of Müllerian 
ducts, is transiently expressed (Carroll et al., 2005) and later, Wnt5a and Wnt7a are 
involved in the proper differentiation of the ducts into uterus, cervix, vagina, and 
oviduct (Miller and Sasson, 1998; Parr and McMahon, 1998). Indeed, mice deficient 
for the Wnt-7a gene completely lack uterine glands (Miller and Sasoon, 1998) and 
oviducts in most animals (Parr and McMahon, 1998), resulting in infertility.  
In human endometrium, published data reveals that Wnt7a is specifically located in 
the luminal epithelium, whereas Wnt5a is restricted to the stromal compartment. 
No significant regulation of Wnt2, -4, -5a, or -7a has been demonstrated in the 
different phases of the menstrual cycle, with the exception of Wnt3 upregulation in 
proliferative endometrium (Tulac et al., 2003). Ovarian hormones regulate Wnt 
signalling in endometrium to maintain the balance between oestrogen-induced 
proliferation and progesterone-driven differentiation (Van der Horst et al., 2012; 
Sonderegger et al., 2010). Wnt molecules (-4,-5a, -6, and -7a) are up regulated by 
oestrogen during the proliferative phase, while in the secretory phase 
progesterone acts as an activator of Wnt signalling inhibitors (Wang et al., 2010). 
Moreover, differential expression of Wnt signalling molecules between pre- and 
postmenopausal endometrial epithelial cells suggests an epithelial stem cell 
population resides in the basalis layer (Nguyen et al., 2012). All the evidence 
gathered suggests that the cyclic remodelling of the endometrium requires 
epithelial-mesenchymal communication, which is probably guided by Wnt family 
members (Tulac et al., 2003), and that the Wnt signalling pathway participates in 
stem cell maintenance and differentiation. 
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Since the relation between Wnt pathway signalling and Lgr5 is clearly established, 
we hypothesized that a mechanism, similar to the gastrointestinal tract where 
epithelial cells in the crypts proliferate in response to activated Wnt signalling 
(Clevers, 2006), could be present in the human endometrium, and that Lgr5 might 
be a potential SSC marker for these cells. 
Our identification of Lgr5 in endometrium (mesodermal origin tissue) is consistent 
with the idea that Lgr5 may be a universal SCC marker. Stem cell niches are usually 
identified based on the expression of specific protein markers on SSCs that can be 
tracked and localized. Different approaches were used by our group in order to 
characterise the expression of Lgr5 in human endometrium. We used in situ 
hybridization, to specifically localize Lgr5 gene expression in cells within the human 
endometrium cellular environment throughout the menstrual cycle, using specific 
riboprobes generated in our laboratory. Results revealed the existence of Lgr5 
positive cells in a restricted epithelial and stromal area, mainly located in the 
perivascular regions and in the lower functionalis, near the basalis layer. Similarly 
results from Lgr5 protein expression in the human endometrium throughout the 
menstrual cycle were obtained. As expected, Lgr5 cells were localized in the 
epithelial glands and perivascular regions of the stromal compartment, most 
frequently in stromal cells, with no apparent differences in the frequency or 
intensity of the signal across the cycle. To support this data, the expression of Lgr5 
protein was also confirmed by western blot analysis, where increased expression in 
the proliferative versus the secretory endometrium was observed, although these 
differences were not statistically significant due to small sample size analysed 
(n=2). However, this data is consistent with an increase in stem cell activity during 
the renewal of the endometrium in the proliferative growth phase.  
The telomerase enzyme, which prevents telomere shortening at each cell division, 
maintains telomere length and is expressed in stem cells, including germ cells, and 
in the niche of several adult tissues. Using telomapping we identified specific ‘hot’ 
regions in the human endometrium, corresponding to the cells with the longest 
telomeres. Interestingly, we co-localized Lgr5 mRNA signals to some of the cells 
with the longest telomeres, suggesting that Lgr5 cells are associated, at least in 
part, with a long-telomere phenotype. The presence of Lgr5 in human 
endometrium, using both mRNA and protein approaches, is a novel finding and 
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combined with our preliminary data suggests that it co-localizes in cells with the 
longest telomeres. Therefore we speculate that Lgr5 may both mark and be 
implicated in the endometrial SSC niche.  
Finally Lrg5 positive cells were isolated by flow cytometry, with percentages of 
1.68% of the total cell population for epithelial cells, and 0.83% for stromal cells. 
The isolation of Lgr5 positive cells from endometrial samples represents a feasible 
method for working with this putative SSC population, enabling different assays to 
be performed. Thus, freshly isolated and labelled cells were used for 
xenotransplantation assays under renal capsule in immunocompromised mice. The 
identification of new putative endometrial tissue formed above the kidney capsule, 
which positively stained for Prussian blue was observed in both the Lgr5 positive 
fraction and Lgr5 negative fraction (in both epithelial and stromal cells). 
Additionally, this de novo formed tissue showed a CD9 and Vm positive phenotype 
(markers of differentiated endometrial cells) in some cells. Previous studies have 
revealed de novo formation of endometrial-like tissue in the kidney capsule with 
different kinds of putative endometrial SSCs. Thus two different groups injected 
around 100,000 or 500,000 SP cells either in the kidney capsule or subcutaneously 
respectively (Masuda et al., 2010; Cervelló et al., 2010; Cervelló et al., 2011), and 
both showed endometrial-like tissue formation and expression of typical 
endometrial markers.  
However, it is known that the SP is a heterogeneous population of stem cells, and 
that a marker for a purified endometrial SSC population is required. Masuda 
discovered a novel marker W5C5, for stromal endometrial SSC, after isolating and 
culturing them, 500,000 W5C5+ cells were injected underneath the kidney capsule, 
reconstituting stromal tissue in vivo (Masuda et al., 2012).  
Clearly, our studies represent the first time that a very low number of cells (2,000 
and 20,000) isolated by a distinctive marker like Lgr5 has been used in an in vivo 
tissue reconstitution assay. Taking all the results obtained in this thesis together, 
we can assume that Lgr5 marker defines the purest endometrial SSC population yet 
described. Nevertheless the regeneration of a well-structured endometrium in vivo 
was inefficient, likely because the niche provided by other endometrial cells was 
missing, and because of the low number of cells used in this new approach. Even 
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with the low number of Lgr5 cells injected some organization into a new structure 
in the kidney seemed to occur, and perhaps this population of cells would behave 
with more SSC-like potency if they were surrounded with an appropriate 
microenvironmental niche. Moreover we detected minimal human tissue-specific 
reconstruction (due to Prussian blue staining) when Lgr5 negative cells were 
injected, further suggesting the essential and vital role of the surrounding 
microenvironmental niche, TA cells, and differentiated cells, in this complex tissue-
renewal process.  
Future Perspectives: Applications in Regenerative Medicine  
Stem cell based therapies, including collection, purification, manipulation, 
characterization, and delivery of cells for therapeutic purposes have existed since 
the first BMTs in 1968 (Gatti et al., 1968). BMSCs include many populations of 
progenitor cells: HSCs, MSCs, SP cells, and MAPCs. From these, MSCs are commonly 
used in the lab, because they are easy to separate from other cells types by their 
adherence in culture, and they constitute an unlimited pool of transplantable cells. 
They have been used in a large number of clinical assays for the treatment of 
different diseases.  
Considering the information complied in this work, we know that the BM 
contributes to the regeneration of endometria after injury by chemotherapy which 
results in damaged to the reproductive system. Indeed published data indicate that 
HSC mobilization does not improve endometrial function per se, hence perhaps 
implying that MSCs represent the pool of cells which respond to this type of 
endometrial damage. MSCs are similar to endometrial stromal cells by nature, 
therefore perhaps making it easier for this cell cohort to enhance endometrial 
tissue renewal. Further studies supporting this hypothesis may result in better 
knowledge of which kinds of cells can best restore endometrial function.  
A recent case report has examined BM derived cells as a possible cell source for 
regenerating endometrium in a patient with Asherman´s syndrome (Nagori et al., 
2011; Gargett and Healy 2011). This pathology is characterized by adhesions and/or 
endometrial fibrosis and atrophic endometrium, most often associated with 
dilation and curettage of the intrauterine cavity, resulting in future obstetric 
complications. The case report described an innovative treatment using autologous 
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BM-derived stem cell populations administered directly into the uterine cavity, 
which regenerated the endometrium sufficiently to enable implantation of a donor 
oocyte IVF embryo and support the following pregnancy. The BM cells used were 
selected with three different markers, CD9, CD90, and CD133 in attempt to isolate 
angiogenesis promoting cells. While CD133 specifies a very rare subset of 
hematopoietic stem cells with endothelial progenitor cell activity, CD90, and CD9 
are both MSC and fibroblast markers (Gargett and Healy 2011). 
In studies to date, the main mechanism of action attributed to transplanted BM-
derived mononuclear cells involves cell-cell contact and secretion of bioactive 
molecules that promote angiogenesis and tissue repair, inhibit scarring, modulate 
inflammatory and immune reactions, and activate tissue-specific progenitor cells, 
rather than by engraftment (Prockop 2009; Caplan 2009). Further clinical assays are 
required to further dissect this mechanism as well as to better understand the 
biology of these different kinds of BM cells.  
Another perspective in this amazing field is tissue engineering, a rapidly expanding 
area of applied biology and biomedical engineering that aims to create artificial 
organs for transplantation, basic research, or drug development. In this context 
reconstruction of the uterus is one of the most ambitious targets in reproductive 
medicine. The design of a tissue engineering scaffold construct into which cells with 
a broad differentiation potential could be incorporated as an autologous cell-based 
therapy could provide many potential new avenues in regenerative medicine 
applications. The process usually starts with a three-dimensional structure called a 
scaffold that is used to support cells as they grow and develop. Skin, blood vessels, 
bladders, trachea, oesophagus, muscle and other types of tissue have all been 
successfully engineered in this way, and some of these tissues have already been 
used to treat human disease (Atala Lab, Wake Forest School of Medicine).  
In literature one recent study reports an assay in which endometrial MSCs are 
incorporated into an elastic scaffold as a treatment to regenerate the damaged 
endopelvic fascia of the vagina wall for women suffering pelvic organ prolapse 
(Gargett laboratory note, not press). In accord with this strategy, we aim to 
eventually construct a uterus de novo, for patients with serial gynaecological 
problems. If our findings truly indicate an endometrial SSC population, autologous 
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Lgr5 positive cells would be an important candidate population for use in 
endometrial restoration, among the many other cells needed to histologically 
reconstruct the uterus. Because SSCs are able to self-renew and to differentiate 
into one or more type of specialized cell, Lgr5 cells with their undifferentiated 
phenotype might represent an important source of cells for this type of tissue 
engineering.  
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VIII. CONCLUSIONS 
The conclusions extracted from this thesis are: 
1. XY cells from bone marrow donors migrate to the recipient’s endometrium, and 
transdifferentiate to the stromal (Vm expressing cells), and epithelial (CD9 
expressing cells) cell compartments contributing to the regeneration of 
endometrial tissue. 
2. XY donor-derived cells were not incorporated into the endometrial side 
population (SP), considered at least in part, to be the somatic stem cell (SSC) 
population. 
3. XY donor-derived cells were not associated with long telomeres.  
4. This evidence demonstrates that XY donor-derived cells can be considered a 
temporal exogenous-source of transdifferentiated endometrial cells rather than a 
cyclic source of bone marrow derived stem cells. 
5. Lgr5 expression is present in the endometrium throughout the menstrual cycle, 
both at the mRNA and protein levels. Lgr5 positive cells are located in the lower 
functionalis, near the basalis layer, and are most frequently found in stromal 
compartment. 
6. Some Lgr5 bearing cells have some of the longest telomeres suggesting they 
have this ‘stemness’ feature.  
7. The proof-of-concept that Lgr5 is an endometrial SSC marker was demonstrated 
by the injection of Lgr5 positive cells in the kidney capsule of NOD-SCID mice, 
leading to the formation of human endometrial-like tissue. 
8. In summary we demonstrate that the bone marrow derived stem cells contribute 
to endometrial regeneration as an exogenous source of cells capable of 
differentiating; whereas Lgr5 can be considered as a marker of the endogenous 
endometrial stem cell niche. 
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ANNEX I. Consentimiento informado para la obtención  análisis de muestras de 
tejido endometrial. 
Estudio: Estudio del origen de las células madre somáticas endometriales  en mujeres con 
enfermedades hematológicas que reciben transplante alogenico de progenitores 
hematopoyéticos de donante masculino.  
Procedimiento médico: BIOPSIA ENDOMETRIAL 
Usted fue sometida a un trasplante alogénico de progenitores hematopoyéticos como 
tratamiento de su enfermedad hematológica. Con el siguiente consentimiento se le pide su 
autorización para participar en un estudio piloto que, básicamente, requiere de la 
realización de una biopsia de endometrio. Con ello pretendemos buscar células madre en 
su endometrio que puedan derivar del donante usado para su trasplante, tal y como sucede 
con su médula ósea las cuales, como usted ya sabe, proceden de dicho donante. 
Dado el interés generado sobre el estudio de células madre adultas, este proyecto en el que 
se le propone participar busca si dichas células están presentes en el endometrio humano. 
Los investigadores que participan en este trabajo ya han descrito la existencia de estas 
células madre adultas endometriales en un modelo animal. 
El endometrio tiene una gran capacidad regenerativa lo que lo convierte en un tejido 
idóneo para llevar a cabo este tipo de estudio. La localización, en una primera parte del 
desarrollo del proyecto y más adelante, el aislamiento, la cuantificación y generación de 
líneas de células madre endometrial procedentes de tejido endometrial humano suponen el 
objetivo central de dicho proyecto. 
Con el fin de que pueda decidir si desea participar en este estudio, usted debe comprender 
las ventajas e inconvenientes del mismo para que sea capaz de tomar una decisión 
informada al respecto. Este proceso es lo que se conoce como consentimiento informado. 
Este consentimiento informado le da información detallada sobre el estudio y además, su 
médico comentará esta información con usted. Cuando haya comprendido el estudio se le 
solicitará que firme este consentimiento informado si desea participar en él. Se le dará una 
copia de este documento para que pueda guardarlo. Su participación en este estudio es 
voluntaria. 
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Descripción del proceso y posibles riesgos: 
La toma de una biopsia se trata de una intervención consistente en la extirpación de un 
fragmento de tejido, con fines diagnósticos y/o terapéuticos. En su caso concreto la biopsia 
se hará de endometrio. Toda intervención quirúrgica, tanto por la propia técnica como por 
el estado de salud de cada paciente (diabetes, cardiopatías, hipertensión, anemia, 
obesidad, edad avanzada...etc.) lleva implícita una serie de posibles complicaciones 
comunes y otras potencialmente más importantes que podrían requerir tratamientos 
complementarios, tanto médicos como quirúrgicos, así como, excepcionalmente, un 
porcentaje mínimo de mortalidad. 
Las complicaciones específicas de la biopsia más frecuentes son: hemorragia (inmediata o 
tardía); infección; quemaduras accidentales en caso de utilizar electrocirugía (tanto en el 
electrodo activo como quemaduras distales); excepcionalmente, reacción vagal con 
lipotimia (desmayo); reacción alérgica al anestésico local. Si en el momento del acto 
quirúrgico surgiera algún imprevisto, el equipo médico podrá modificar la técnica quirúrgica 
habitual o programada. 
Alternativas: 
No se contemplan alternativas para la obtención de tejido endometrial en el contexto de 
este estudio distintas a la biopsia endometrial clásica. 
Riesgos personalizados: 
Derivados de la situación particular de cada paciente (cumplimentar si procede): 
.................................................................................................................................................... 
Aspectos legales: 
 1.- Las muestras serán almacenadas utilizando códigos alfanuméricos sin que en el registro 
conste el nombre u otros datos personales del enfermo, a excepción de su número de 
historia clínica. El responsable de dicho registro será el Dr. D. Miguel Ángel Sanz Alonso. A 
estos datos sólo tendrán acceso los componentes de los diferentes grupos investigadores y 
centros encargados del paciente, manteniendo la confidencialidad de los datos. Estos datos 
están protegidos por la Ley 15/99 de Protección de Datos de Carácter Personal. De acuerdo 
con dicha ley usted puede ejercer el derecho de acceso, rectificación, cancelación y 
oposición en cualquier momento solicitándolo por escrito a la siguiente dirección: 
 Servicio de Hematología y Hemoterapia 
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 Hospital Universitario La Fe. Edificio Central. Planta Baja. 
 Avda. Campanar 21, Valencia 46009 
 Teléfono de contacto: 963862745 
De la misma manera usted podrá solicitar la destrucción de sus muestras almacenadas 
solicitándolo por escrito a la misma dirección. 
2.- Los estudios de investigación que se vayan planteando serán los más indicados en cada 
momento al conocimiento científico vigente. Usted puede no dar su consentimiento sin que 
ello suponga ningún perjuicio para usted. 
3. Los resultados de las investigaciones serán públicos. 
4. El material biológico recogido y almacenado pasará a ser propiedad de las autoridades 
competentes y su destino y plazo para dicha propiedad será decidido por las autoridades 
competentes, sin perjuicio de sus derechos individuales. 
5.- Bajo ningún concepto y en ningún momento las muestras serán motivo de lucro directo, 
bien sea por la venta del material o de los derechos para realizar estudios sobre los mismos. 
6.- En algunos casos será necesario enviar la muestra a otro centro para su almacenamiento 
y/o para llevar a cabo los estudios en su totalidad o parcialmente. 
7.- Es posible que de las investigaciones no se derive ningún beneficio directo para el 
paciente. 
8.- Si con posterioridad a haber dado el consentimiento para la realización de la prueba 
usted quisiera revocarlo, podría hacerlo libremente en cualquier momento. 
9.- En ningún momento ni bajo ningún concepto dicha información o dichas muestras 
biológicas serán empleadas con otros fines diferentes a los aquí expuestos. En caso de que 
así fuera, sería informado y se solicitaría un nuevo consentimiento para los mismos. 
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CONSENTIMIENTO DE OBTENCIÓN Y  ALMACENAMIENTO DE MUESTRAS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apellidos:............................................................................................................................... 
Nombre:................................................................................................................................ 
DECLARACIONES Y FIRMAS: 
Declaración del enfermo:  
 He sido informado por el médico abajo mencionado de: 
- las ventajas e inconvenientes del procedimiento arriba indicado 
- las posibles alternativas al mismo  
 He podido formular todas las preguntas que he creído oportunas. 
 He comprendido la información recibida y puedo retirar mi consentimiento: 
- Cuando quiera 
- Sin tener que dar explicaciones 
- Sin que esto repercuta en mis cuidados médicos 
 
Dicho lo cual, OTORGO LIBREMENTE MI CONSENTIMIENTO para el procedimiento 
Nombre............................................................          Firma: ............................. 
No otorgo el consentimiento para el almacenamiento y use descrito de muestras 
Nombre:............................................................         Firma: ............................. 
Declaración del médico, de que ha informado debidamente al paciente. 
Nombre: .............................................................      Firma: ............................... 
Declaración del familiar, persona allegada o representante legal, en su caso, de que han recibido la 
información por incompetencia del paciente. 
Nombre ..............................................................       Firma ................................. 
 
REVOCACIÓN 
Nombre  D/Dª......................................................................................................................  
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ANNEX II. Consentimiento informado para la obtención de muestras de tejido 
endometrial. 
TÍTULO DEL ESTUDIO: Demostración de que Leucine-rich repeat-containing G protein 
coupled receptor 5(Lgr5) es un marcador de células madre endometriales. Desde los 
modelos animales hasta su contribución en terapia celular e ingeniería tisular. 
CÓDIGO DEL PROMOTOR: 1203-C-098-IC-F 
PROMOTOR: Fundación IVI e Instituto Universitario IVI-Universidad de Valencia-INCLIVA 
INVESTIGADOR PRINCIPAL/DPTO. /EMAIL: Dr. Carlos Simón / Departamento de Ginecología 
y Obstetricia-Fundación IVI/ Carlos.Simon@ivi.es 
CENTRO: Fundación IVI 
1.INTRODUCCIÓN 
Nos dirigimos a Vd. para informarle sobre un estudio de investigación, aprobado por el 
Comité de Ética, en el que se le invita a participar. 
Nuestra intención es tan sólo que Vd. reciba la información correcta y suficiente para que 
pueda evaluar y juzgar, si quiere o no participar en este estudio.  
Para ello le ruego lea esta hoja informativa con atención, pudiendo consultar con las 
personas que considere oportuno, y nosotros le aclararemos las dudas que le puedan 
surgir.  
2.PARTICIPACIÓN VOLUNTARIA 
Debe saber que su participación en este estudio es voluntaria, y que puede decidir no 
participar, o cambiar su decisión y retirar su consentimiento en cualquier momento, sin que 
por ello se altere la relación con su médico ni produzca perjuicio alguno en su tratamiento.  
3. DESCRIPCIÓN GENERAL DEL ESTUDIO 
Nuestro equipo investigador trabaja desde hace años en la búsqueda de células madre 
adultas en el útero y más concretamente en el endometrio, que es la capa de tejido mucoso 
que recubre la cavidad uterina. El gran problema que existe hoy en día es que debido a la 
novedad de este tipo celular, tenemos grandes incógnitas en nuestras investigaciones. Una 
de ellas y que es el principal objetivo de nuestro proyecto científico es buscar un marcador 
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celular, una señal concreta que tengan estas células y que nos permitan identificarla dentro 
del conjunto de células que componen el organismo, o en nuestro caso el endometrio. 
Estudiaremos las células que obtendremos de las biopsias endometriales.  
El objetivo de la toma de muestra es conocer la implicación y existencia del marcador Lgr5 
en las pacientes/donantes mediante una toma de muestra endometrial. La toma de 
muestra o biopsia endometrial se realizará en el momento de la punción ovocitaria; este 
protocolo no altera ni interrumpe para nada el éxito de  la técnica de extracción de 
ovocitos. La toma de biopsia endometrial no supone riesgo alguno para la paciente y 
tampoco dolor ya que se realiza en el momento de la punción ovocitaria, por lo tanto 
cuando Vd. está en quirófano y sedada, bajo anestesia general. Vd. sólo será sometida a 
una toma de biopsia el día de la punción y no es necesario que vuelva para una nueva toma. 
Todo esto se lleva a cabo dentro del propio ciclo de donación, con la medicación propia de 
este proceso. 
Las muestras  serán: anónimas (no es posible su vinculación a una persona identificable por 
nombre, dirección, número de historia clínica...). Tras la extracción de la muestra se le 
asignará un código que será su único método de identificación. La muestra se conservará en 
un lugar seguro y de acceso restringido. Se conservará por un período de tiempo limitado y 
proporcional al tiempo necesario para llevar a cabo los objetivos establecidos. La muestra 
se consumirá completamente para el estudio indicado en este proyecto. 
Las células madre han adquirido gran importancia en el área de la Biología en los últimos 
años. Estas células madre han generado grandes expectativas en investigadores y pacientes, 
y en la sociedad en general. Existen diferentes tipos de células madre, entre los más 
destacados están las células madre embrionarias (derivan de la masa celular interna del 
embrión) y las células madre somáticas o adultas (CMS), siendo estas últimas las células de 
interés de nuestro estudio. 
Las CMS son células adultas pero indiferenciadas/inmaduras y por lo tanto parecidas a las 
embrionarias pero que se encuentran en los tejidos/órganos de los seres adultos. Son las 
responsables de la regeneración de nuestros órganos y tejidos de forma natural, además de 
saberse hoy en día que su degeneración puede dar lugar  a diferentes tipos de cáncer.  
Por lo tanto debido a la falta de marcadores específicos de CMS endometriales o del 
endometrio, nuestro laboratorio ha trabajado en la búsqueda de células madre de 
endometrio en ratones utilizando diferentes técnicas (Cervelló et al., 2007), y también en el 
modelo humano mediante una técnica basada en características celulares (Cervelló et al., 
2010, Cervelló et al., 2011, Cervelló et al., 2012). Pero no hemos descubierto aún un 
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marcador universal para la detección de estas células madre adultas o somáticas en el 
endometrio.  
Aún así existen evidencias científicas en intestino y piel que han proporcionado datos 
sólidos que muestran que una proteína de superficie celular llamada Leucine-rich repeat-
containing G-protein coupled receptor 5 (Lgr5) es un marcador específico de las CMS en 
estos órganos y tejidos.  
Nosotros hemos trabajado con esta misma proteína con el fin de conocer su papel en el 
endometrio y nuestros resultados preliminares han proporcionado datos muy positivos 
para centrarnos en un estudio mucho más concreto de este posible marcador celular.  
4. BENEFICIOS Y RIESGOS DERIVADOS DE SU PARTICIPACIÓN EN EL ESTUDIO. 
No existe ningún riesgo para la salud que derive de la toma de muestras de biopsia 
endometrial en las pacientes/donantes. 
Es muy posible que los resultados obtenidos en esta investigación tengan poco valor 
diagnóstico o predictivo para usted, pero podrá ayudar a conocer la presencia de células 
madre somáticas en el útero y el tratamiento de futuros pacientes con diferentes tipos de 
patología.  
Los beneficios esperados derivados de este proyecto son inmensamente útiles para la 
sociedad y para la Medicina en general.  
5. CONFIDENCIALIDAD Y TRATAMIENTO DE DATOS 
El tratamiento, la comunicación y la cesión de los datos de carácter personal de todos los 
sujetos participantes se ajustará a lo dispuesto en la Ley Orgánica 15/99 de 13 de diciembre 
de protección de datos de carácter personal. De acuerdo a lo que establece la legislación 
mencionada, usted puede ejercer los derechos de acceso, modificación, oposición y 
cancelación de datos, para lo cual se deberá dirigir a su médico del estudio. 
Los datos recogidos para el estudio estarán identificados mediante un código y sólo su 
médico del estudio/colaboradores podrán relacionar dichos datos con Usted y con su 
historia clínica. Por lo tanto, su identidad no será revelada a persona alguna salvo 
excepciones en caso de urgencia médica o requerimiento legal. El acceso a su información 
personal quedará restringido al médico del estudio/colaboradores, autoridades sanitarias, 
al Comité Ético de Investigación Clínica y personal autorizado por el promotor, cuando lo 
precisen para comprobar los datos y procedimientos del estudio, pero siempre 
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manteniendo la confidencialidad de los mismos de acuerdo a la legislación vigente en 
nuestro país. 
6. SEGURO 
El Promotor del Estudio, esto es, la Instituto Universitario IVI-Valencia, dispone de una 
Póliza de Seguros de Responsabilidad Civil en vigor que se ajusta a la legislación vigente.   
7. COMPENSACIÓN ECONÓMICA  
El Investigador del estudio es el responsable de gestionar la financiación del mismo. La 
paciente no recibirá remuneración alguna. Su participación en el estudio no le supondrá 
ningún gasto adicional al tratamiento que se le practica en la clínica. 
Aun así queremos informar al participante la gratuidad de la transmisión de la propiedad de 
órganos, tejidos y células siempre que estén destinados meramente a la investigación 
científica. 
OTRA INFORMACIÓN RELEVANTE  
Cualquier nueva información relevante referente al estudio y que pueda afectar a su 
disposición para participar en el estudio, que se descubra durante su participación, le será 
comunicada por su médico lo antes posible. Si usted decide retirar el consentimiento para 
participar en este estudio, ningún dato nuevo será añadido a la base de datos y, puede 
exigir la destrucción de todas las muestras identificables previamente retenidas para evitar 
la realización de nuevos análisis.  
Al firmar la hoja de consentimiento adjunta, se compromete a cumplir con los 
procedimientos del estudio que se le han expuesto.  
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CONSENTIMIENTO INFORMADO PARA INVESTIGACIÓN  CON MUESTRAS BIOLÓGICAS 
HUMANAS ANONIMIZADAS 
TITULO DEL PROYECTO: Demostración de que Leucine-rich repeat-containing G-protein 
coupled receptor 5(Lgr5) es un marcador de células madre endometriales. Desde los 
modelos animales hasta su contribución en terapia celular e ingeniería tisular. 
Código: 1203-C-098-IC-F 
Fecha: _______________________ Nº de historia: ___________________ 
Dª. (nombre y dos apellidos) ______________________________________ 
CON DNI Nº ____________  Y DOMICILIO EN_________________________ 
DECLARO que he leído la Hoja de Información del Proyecto de Investigación que se me ha 
entregado, que he podido hacer preguntas y que he recibido suficiente información por 
parte del investigador D./Dª ______________________________, quien me ha explicado 
todos los pormenores del mismo, en particular de: 
1.-La finalidad de la investigación o de la línea de investigación para la que consiento. 
2.- De los beneficios esperados con la misma. 
3.- De los posibles inconvenientes vinculados con la donación y obtención de la muestra, 
incluida la posibilidad de ser contactado con posterioridad con el fin de recabar nuevos 
datos u obtener otras muestras. 
4.- De la identidad del responsable de esta investigación, el Dr. ______________ 
Declaro además que comprendo que mi participación es voluntaria, por lo que puedo 
retirarme de la investigación: 
1º Cuando lo desee. 
2º Sin tener que dar explicaciones. 
3º Sin que esto repercuta en mis cuidados médicos. 
Presto libremente mi conformidad para participar en esta investigación y doy mi 
consentimiento para el acceso y utilización de mis datos en las condiciones detalladas en la 
Hoja de Información que se me ha entregado. 
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Firma de la donante:     Firma del médico/investigador: 
       
 
Nombre:         Nombre: 
Fecha:         Fecha:   
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ANNEX III. Solution composition used in the in situ hybridization process. 
 
 
SOLUTION COMPOSITION 
1× Proteinase K Buffer  1M Tris pH8 +  250mM EDTA pH 8 + dH2O 
 
10× PK Stop Solution  Glycine +10× PBS-DEPC  
20× SSC-buffer  NaCl + Tri sodium citrate pH 7 
 
Buffer 1 pH 7.5 Maleic acid + NaCl + H2O miliQ   
10× Bloking Solution  Bloking reagent  + Buffer 1 (10×) Use 1x Solution  
5× RNAse Buffer NaCl +  1M Tris pH 7.5 + 250mM EDTA pH 8 
 
Ribonucleic Acid 
Solution  
ssDNA 10mg/mL + tRNA 25mg/Ml + total 
RNA25mg/mL 
TTAA Triethanolamine + H2O DEPC + Acetic Anhydride 
Buffer 3 Tris pH 9.5 
MgCl 
NaCl 
dH2O DEPC 
Hybridization Buffer  Deionized Formamide  
1M Tris pH 7.4 
250mM EDTA pH8 
5M NaCl 
Dextran sulphate 
50x Denhardt's Solution 
H2O DEPC  
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